MX2008012539A

MX2008012539A - Thiazolyldihydroindazoles.

Info

Publication number: MX2008012539A
Application number: MX2008012539A
Authority: MX
Inventors: Matthias Hoffmann; Matthias Grauert; Trixi Brandl; Steffen Breitfelder; Christoph Hoenke; Udo Maier; Stefan Scheuerer; Alexander Pautsch; Anne T Joergensen; Klaus Erb; Michael Pieper; Ingo Pragst
Original assignee: Boehringer Ingelheim Int
Priority date: 2006-04-06
Filing date: 2007-03-27
Publication date: 2008-10-10
Also published as: TW200806680A; IL194496A0; US20090093474A1; BRPI0709743A2; US20070238718A1; EP2018387A1; AR060266A1; CN101466717A; RU2008143557A; ZA200807821B; JP2009532417A; WO2007115933A1; CA2647295A1; AU2007236047A1; KR20090026129A

Abstract

The present invention relates to novel thiazolyldihydroindazoles of the general formula (I) where the R1, R2 and R3 radicals are each as defined in the claims and the description, to their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, and where appropriate to their pharmacologically safe acid addition salts, solvates and hydrates, and to processes for preparing these thiazolyldihydroindazoles and to their use as medicaments.

Description

TIAZOLIL-DIHIDRO-INDAZOLES The present invention relates to novel thiazolyl-dihydro-indazoles of the general formula (I) (I) wherein the radicals R1, R2 and R3 have the meanings mentioned in the claims and in the descriptive part, their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, as well as, optionally, their salts by the addition of acids, pharmacologically harmless solvates and hydrates, as well as processes for the preparation of these thiazolyl-dihydro-indazoles and their use as medicaments. BACKGROUND OF THE INVENTION Phosphatidylinositol-3-kinases (PI3-kinases) are a subfamily of lipid kinases, which catalyze the transfer of a phosphate radical to the 3 'position of the inositol ring of phosphoinositides. They participate in numerous cellular processes such as, for example, processes of cell development and differentiation, in the control of cytoskeletal alterations and in the regulation of intracellular transport processes (Vanhaesebroeck et al., Annu Rev Biochem., 2001; : 535-602). PI3-kinases may play a role in many tumors such as, for example, breast cancer, ovarian carcinoma or also pancreas, in types of tumors such as carcinomas of the colon, breast or lung, but also, above all, in autoimmune diseases such as, for example, Crohn's disease or rheumatoid arthritis, or in the cardiovascular system such as, for example, in the formation of cardiac hypertrophy (Oudit et al., Circulation, 2003 Oct 28; 108 (17): 2147-52). PI3-kinase modulators may represent a possibility for anti-inflammatory therapy with comparatively few side effects (Ward and Finan, Curr Opin Pharmacol, 2003 Aug; 3 (4): 426-34). PI3-kinase inhibitors for the treatment of inflammatory diseases are known in the literature. Thus, WO 03/072557 discloses 5-phenylthiazole derivatives, WO 04/029055 shows condensed azolpyrimidines and WO 04/007491 shows benzene derivatives linked with azolidinone-vinyl. In addition, from the two documents WO 04/052373 and WO 04/056820 benzoxazine and benzoxazin-3-one derivatives are disclosed. It is the object of the present invention to provide new compounds, which, by virtue of their pharmaceutical activity as modulator of PI3-kinases, can be used in the therapeutic field for the treatment of inflammatory or allergic diseases. By way of example, inflammatory and allergic respiratory diseases, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic disease states, in which reactions are involved, are to be mentioned here. autoimmune or inflammation of the kidneys.

DETAILED DESCRIPTION OF THE INVENTION Surprisingly, it has been found that the aforementioned mission is solved by compounds of the formula (I), wherein the radicals R to R3 have the meanings mentioned in the following. In particular, it was found that compounds of the formula (I) act as inhibitors of PI3-kinases, especially as inhibitors of the PI3-kinase gamma. Accordingly, the compounds according to the invention can be used, for example, for the treatment of diseases of the respiratory tract. Therefore, the present invention relates to compounds of the general formula (I), wherein R 1 signifies hydrogen, CO-CH 3, CO-CH 2 -R 4, CO-CHMe-R 4, CO-OR 4, CO-SR 4, CO-NH 2 or CO-NHR 4; R 2 means a radical selected from the group consisting of C 3-6 cycloalkyl, alkyl d-4-cycloalkyl C 3-6, alkenyl C 2-4-cycloalkyl C 3-6) alkynyl C 2-4-cycloalkyl C 3-6, cycloalkenyl C 5-6, alkyl Ci-6-cycloalkenyl C5-6, C2-4 alkenyl-C5-6 alkenyl, C2-4 alkynyl-C5-4 cycloalkenyl, C5-6 cycloalkynyl, Ci-6-cycloalkynyl C5-6 alkyl, C2- alkenyl-cycloalkynyl C5 -6 and C 2-4 alkynyl-C 5-6 cycloalkynyl, which may optionally be substituted with one or two of the radicals CH 3, F, OCH3, OH or NH2; R3 means a radical selected from the group consisting of C6-Ci4 aryl, Ci-6-aryl, C6-Ci4 aryl, C2-6 alkenyl-C6-Ci4 aryl, C2-6 alkynyl-C6-Ci aryl, C5-C10 heteroaryl, Ci-i2-alkyl C5-C10 heteroaryl, C3-i2-alkenyl C5-C10 heteroaryl, C3- 12-alkynyl C5-C10 heteroaryl, C3-6cycloalkyl, Ci-6 alkyl-C3-6 cycloalkyl, alkenyl C2-4- C 3-6 cycloalkyl, C 2-4 alkynyl-C 3-6 cycloalkyl, C 5-6 cycloalkenyl, C 1-6 alkylcycloalkenyl, C 2-4 alkenyl C 5-6 cycloalkenyl, C 2-4 alkynyl C 5-6 cycloalkenyl, C5-6 cycloalkynyl, Ci-6-cycloalkynyl C5-6 alkyl, C2-4 alkenyl-C5-6 cycloalkynyl and C2-4 alkynyl-cycloalkynyl C5-6, which may optionally be substituted with a radical R5 and up to three radicals R6; optionally substituted, wherein n, m, independently of one another, means 1 or 2; R4 means an optionally substituted radical selected from the group consisting of Ci-4alkyl, C2-io alkenyl, C2-io alkynyl, C3-6 cycloalkyl-C1-4alkyl, C3-6 cycloalkyl-C3-alkenyl, C3-cycloalkyl- 6-C3-yl alkynyl, aryl Ce-C, aryl C6-Ci4-alkyl Ci-4, heteroaryl C5-C10, heteroaryl Cs-C-io-alkyl Ci-4 and haloalkyl; R5 means CONR8R9, NR8COR9, NR8R9, OR9 and -C1-4alkyl-CONR8R9; R6, the same or different, mean F, Cl, Br, OH, CN, CF3, CHF2 or a possibly substituted radical, selected from the group consisting of O-alkyl Ci-3, O-alkenyl C3-, O-alkynyl C3-4 , Ci-3 alkyl, C 2-6 alkenyl and C 2-3 alkynyl, C 3-6 cycloalkyl-Ci-4 alkyl, C 3-6 cycloalkyl-C 2-4 alkenyl, C 3-6 cycloalkyl-alkynyl C2-4, C5-6cycloalkenyl-Ci-4 alkyl, C5-6 cycloalkenyl-C3-alkenyl, C5-6 cycloalkenyl-C2-4 alkynyl, aryl C6-Ci4-Ci- alkyl, aryl C6-Ci4-alkenyl C2 -4, C6-C14 aryl C2- alkynyl, C5-C10 heteroarylC1-4 alkyl, C5-4 heteroaryl C2-4 alkenyl and C5-4 heteroarylCi0-alkynyl > R7 means hydrogen, COR9, CONR8R9 or a radical, selected from the group consisting of CMO alkyl, C3-0 alkenyl, C3-10 alkynyl, C3-6 cycloalkylC1-4 alkyl, C3-6 cycloalkylC3-alkenyl, cycloalkyl C3-6-C3-C18 alkynyl C5-6 cycloalkenyl-Ci-4 alkyl, C5-6 cycloalkenyl-C3-10 alkenyl, C5-6 cycloalkenyl-C3-10 alkynyl, C6-Ci4 aryl, Ci-10-aryl C6 alkyl Ci, C2-io-alkenyl C6-Ci4 aryl, C2-io-alkynyl C6-Ci4 aryl, C5-C10 heteroaryl, alkyl-heteroaryl Ci.i2 C5-C10) alkenyl C3-i2-C5-C10 heteroaryl and C3 alkynyl -i2-C5-C10 heteroaryl, which may optionally be substituted with a radical R14 and with a radical R15; R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-10 alkenyl. C3-10 alkynyl, C3-6 cycloalkyl-d-4 alkyl, C3-6 cycloalkyl-C3-alkenyl, C3-6 cycloalkyl-C3-10 alkynyl, C5-6 cycloalkenyl-C1-4 alkyl, C5-6 cycloalkenyl C3-10 alkenyl. C5-6 cycloalkenyl-C3-10 alkynyl CC, C6-Ci4 aryl-alkyl, aryl-C1 C6-i0 alkenyl C3) C6-Ci4 aryl and alkynyl C3-10, C5-C10 heteroaryl, heteroaryl-Cs-alkyl Cm Ci-4, heteroaryl Cs-Cio-alkenyl Ci-4, heteroaryl C5-Ci0-alkynyl Ci-, alkyl C -4-O-C2-4 alkyl, alkyl Ci-4-O-alkenyl C -6 and alkyl Ci- 4-O-C4-6 alkynyl; R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of alkylC2, C3-12 alkenyl, C3-12 alkynyl, C3-6 cycloalkyl-alkyl Ci-12, C3-6cycloalkyl-C3-12 alkenyl, C3-6 alkynyl C3-i2-cycloalkenyl C5- Ci- 6-alkyl, C5-6-cycloalkenyl C3-i0 alkenyl, cycloalkenyl C5-6-alkynyl C3 -i0, aryl C6-Ci4-C1-12 alkyl, aryl C6-Ci4-alkenyl C3-12, aryl C6-Ci4-alkynyl C3-12, aryl C6-Ci4, alkyl Ci-i2-aryl C6-Ci4, alkenyl C2 i2 C6-Ci4-aryl, C2-i2-alkynyl C6-Ci, C5-C10 heteroaryl, C5-Cio heteroaryl 1-12 alkyl, heteroaryl C5-C- | 0-C3-i2 alkenyl, C5-Ci0 heteroaryl C3-12 -alkynyl, C3-s cycloalkyl, C5- 8, NR 1R12-C3-8 cycloalkyl, C5-8 cycloalkenyl-NR11R12 and NR 1R1 -cycloalkynyl C5-8 heterocycloalkyl radical or denotes a C3-8- (CH2) q, optionally substituted which contains at least one NR10 group in the 3- to 8-membered heterocycle, or together form a saturated or unsaturated 4 to 7-membered alkyl bridge, optionally containing an O atom or a group S (0) p, where p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a 5- to 6-membered heterocycle, which optionally contains another N atom and which is optionally substituted with a radical selected from the group consisting of R10, NR11R12 and NR11 Realkyl Ci-4, or means a radical wherein z, q, g, d, independently of one another, means 1, 2 or 3; R 0 represents hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-C0 alkenyl, C3-C0 alkynyl, C3-7 cycloalkylC1-10 alkyl, C3-7 cycloalkylC3-alkenyl , C3-7-cycloalkyl-C3-alkynyl, C3-7cycloalkyl, Ci-6-cycloalkyl, C3-7 cycloalkyl, C2-4-alkenyl, C3-cycloalkyl, C2-4-alkynyl, C3-7 cycloalkyl, tetrahydropyranyl, and (NR4) 2CH -alkyl CMO, R11, R12, equal or different, mean hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-io alkenyl, C3-10 alkynyl, C3-6 cycloalkylC1-4 alkyl and cycloalkyl C3-6 or R11 and R12 together form an alkyl chain of 4 to 7 members, optionally containing a heteroatom; R 13 means F, Cl, Br, OH, CN, CF 3, CHF 2 or C 1-4 alkyl-O-, R 14 signifies NR R 12 or a C 3-8 heterocycloalkyl radical (CH 2) q, optionally substituted containing at least one group NR 10 in the 3 to 8 membered heterocycle, or R 13 R 4 together form a saturated or unsaturated 4 to 7 membered alkyl bridge, optionally containing an O atom or a S (O) p group, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereoisomers and their mixtures, as well as, eventually, their salts by the addition of pharmacologically harmless acids, solvates and hydrates.

Preference is given to compounds of the formula (I), in which R and R3 to R14 can have the indicated meanings and R2 means a radical, selected from the group consisting of C3-6 cycloalkyl, Ci-6-cycloalkyl C3-6alkyl and C2-alkenyl C3-6-cycloalkyl, which may optionally be substituted with one or two of the radicals CH3, F, OCH3, OH or NH2, In addition, compounds of the formula (I) are preferred, wherein R1, R2 and R4 a R14 may have the indicated meanings and R3 signifies a radical, selected from the group consisting of phenyl and C5-6 cycloalkyl, which may optionally be substituted with a radical R5 and with up to three radicals R6, or , optionally substituted, wherein n, m, independently of one another, means 1 or 2. Further, compounds of the formula (I) are preferred, wherein R1 to R7 and R10 to R14 may have the indicated meanings and R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of C-MO alkyl, C3-io alkenyl. alkynyl 03-10 and alkyl Ci-4-O-alkyl R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-i2 alkyl, C3-y2 alkenyl, C3-12 alkynyl, C3-6 cycloalkyl-C1-i2 alkyl, C6-Ci4 aryl, Ci-i2 alkyl-C-6-aryl, C2-aryl2-aryl C6-C14, C2-C2-alkynyl-C6-Ci4-aryl, C5-C10-heteroaryl, C5-C10-heteroaryl-C1-C2-alkyl, C3-C2-heteroaryl-alkenyl, C3-C2-heteroaryl-alkynyl) C3-8-cycloalkyl, C5-cycloalkenyl -8 and NR11R12- C3-8 cycloalkyl, or means a C3-8- (CH2) q-, optionally substituted heterocyclealkyl, containing at least one group NR10 in the 3- to 8-membered heterocycle, or R8 and R9 together form a 4 to 7 membered alkyl bridge, saturated or unsaturated, optionally containing an O atom or a S (O) p group, wherein p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a 5- to 6-membered heterocycle, which optionally contains another N atom and which is optionally substituted with a radical selected from the group consisting of R10, NR1 R12 and NR11R12C4alkyl, or means a radical wherein z, q, g, d, independently of one another, means 1, 2 or 3. Further, compounds of the formula (I) are preferred, wherein R1 to R7 and R10 to R14 may have the indicated meanings and R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-10 alkenyl, C3-i0 alkynyl and Ci-4-O-alkyl alkyl R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-12 alkyl, C3-alkenyl2, C3-12 alkynyl, C3-6 cycloalkylC1-12alkyl, C6-Ci4 aryl, alkyl C6-C14, C2-i2 alkenyl C6-Ci4 aryl, alkynyl 02-12-C6-Ci4 aryl C5-C10 heteroaryl, C5-Ci0 heteroaryl Ci-12 alkyl, C3-12 heteroaryl-alkenyl, C3-12 heteroaryl-alkynyl i2, cycloalkyl CZ-B, C5-8 cycloalkenyl and NR11 R12-C3-8 cycloalkyl, or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A1 2) R8 and R9 together form an alkyl bridge of 4 to 7 members, saturated or unsaturated, which optionally contains an O atom or a S (0) PI group wherein p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a radical, optionally substituted, selected from the group consisting of the general formulas (B1) to (B8) wherein?, q, g, d, independently of one another, means 1, 2 or 3. Further, compounds of the formula (I) are preferred, wherein R1 to R8 and R10 to R12 may have the meanings indicated and R7 means COR9 or CONR8R9. Further, compounds of the formula (I) are preferred, wherein R1 to R5 and R7 to R14 may have the indicated meanings and R6, same or different, mean F, Cl, CF3, or an O-alkyl radical Ci-3 or Ci-3 alkyl, optionally substituted. Further, compounds of the formula (I) are preferred, wherein R 4a R 6 and R 10a R 12 may have bs indicated meanings and R 1 means CO-CH 3, CO-CH 2 -R 4 R 2 means cyclopropyl, which may optionally be substituted with one or two of the radicals CH3, F, OCH3, OH or NH2, R3 means optionally substituted, wherein n, m, independently of one another, means 1 or 2; R7 means hydrogen, COR9 or CONR8R9, R8 means hydrogen or CMO alkyl, R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of C3-8 cycloalkyl and NR1 1 R12-C3-8 cycloalkyl, or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12) ) > "< 5 (A12) OR NR8R9 means a 5- to 6-membered heterocycle, containing 1 to 3 N atoms, which is optionally substituted by a radical selected from the group consisting of R10, NR 1 R 12 and NR 11 R 12 C 1-4 alkyl. Particularly preferred are compounds of the formula (I), wherein R a R 6 and R 10 to R 2 may have the indicated meanings and R 1 signifies CO-CH 3, CO-CH 2 -R 4; R 2 means C 3-6 cycloalkyl, which may optionally be substituted with one or two of the radicals CH 3, F, OCH 3, OH or NH 2; R3 means a radical, selected from the group consisting of phenyl and C5-6 cycloalkyl, which may optionally be substituted with an R5 and with up to three R6, R5 signifies NR8R9, CONR8R9, NR8COR9 or - C1-4alkyl-CONR8R9; R6, the same or different, mean F, Cl, Br, CF3 or an optionally substituted radical, selected from the group consisting of O-C ^ alkyl, Cw alkyl, cycloalkyl Q-C-alkyl and aryl rCi 4 -alkyl Cw, R 8 is hydrogen or optionally substituted CMO alkyl, R 9 is hydrogen or a radical, optionally substituted, selected from the group consisting of C 1-12 alkyl, cycloalkyl Ci-12-aryl C6-Ci4 alkyl, C5-C10 heteroaryl, C5-Cio heteroaryl-C1.12 alkyl, dclolalkyl CM, cycloalkenyl C & E and NR 1R12-cycloalkyl C ^, or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12) (A10) (A11) (A12) R8 and R9 together form an alkyl bridge of 4 to 7 members, saturated or unsaturated, which optionally contains an O atom or a S (O) p group, where p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a radical, optionally substituted, selected from the group consisting of the general formulas (B1) to (B8) wherein z, q, g, d, independently of one another, means 1, 2 or 3. R 10 means hydrogen or an optionally substituted radical, selected from the group consisting of C 1-4 alkyl, C 3-7 cycloalkyl-CMO alkyl, cycloalkyl C3-7, Ci-6-cycloalkyl C3-7 alkyl, tetrahydropyranyl and (NR4) 2CH-C ^ o alkyl.

Another subject of the invention are compounds of the formula (I) for use as medicaments. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of diseases, in whose pathology an activity of PI3-kinases participates, in which therapeutically effective doses of the compounds of the formula (I) can display a therapeutic utility. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of inflammatory and allergic diseases of the respiratory tract. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of a disease that is selected from the group consisting of chronic bronchitis, acute bronchitis, bronchitis as a consequence of bacterial or viral infection u fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis , lack of alpha-1-antitrypsin, cough, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary edema, pneumonitis by virtue of different genesis, such as induced by irradiation or by infectious aspiration or collagenosis, such as lupus erythematosus, systemic scleroderma, sarcoidosis and Boeck's disease. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of inflammatory and allergic diseases of the skin. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of a disease, which is selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, Alopecia areata (fall circular of the hair), erythema exudative multiforme (Stevens-Johnson syndrome), dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria), lupus erythematosus, follicular and superficial pyoderma, endogenous and exogenous acne, acne rosacea, as well as other diseases of the inflammatory skin and allergic or proliferating. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of inflammations in the eye. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of a disease, which is selected from the group consisting of inflammation of the conjunctiva (conjunctivitis) of different types such as, for example, by infections with fungi or bacteria, allergic conjunctivitis, irritant conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of diseases of the nasal mucosa. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of a disease, which is selected from the group consisting of allergic dermatitis, allergic sinusitis and nasal polyps.

Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of inflammatory or allergic conditions, in which autoimmune reactions take part. Another object of the invention is the use of the compounds of the formula (I), for the preparation of a medicament for the treatment of a disease, which is selected from the group consisting of Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, rheumatoid spondylitis. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of inflammations of the kidneys. Another object of the invention is the use of the compounds of the formula (I) for the preparation of a medicament for the treatment of a disease, which is selected from the group consisting of glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome. According to the invention, a pharmaceutical formulation containing a compound of the formula (I) is of particular importance. A pharmaceutical formulation applicable by inhalation containing a compound of the formula (I) is preferred. In addition, an orally applicable pharmaceutical formulation containing a compound of the formula (I) is preferred. Another object of the invention are compounds of the general formula (VI) wherein R2 and Y can have the indicated meanings, and R3 'means a radical, optionally substituted, selected from the group consisting of 4-PhCOOMe, 4-PhNO2 and 4-piperidyl, cis / trans-4-alkoxycarbonylcylohexyl, 4-methoxycarbonyl- methyl-phenyl, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and mixtures thereof, as well as, optionally, their salts by the addition of pharmacologically harmless acids. Another object of the invention are compounds of the general formula (IX) wherein R2, R6 and Y can have the indicated meanings, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids. Another object of the invention are compounds of the general formula (VII) (VI I) wherein R2, R6 and Y can have the indicated meanings, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids. Terms and expressions and definitions used As alkyl groups, as well as alkyl groups that are components of other radicals, are designated branched and unbranched alkyl groups, with 1 to 10 carbon atoms, preferably 1-6, particularly preferably 1- 4 carbon atoms, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl are mentioned. If not otherwise mentioned, the propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl mentioned above all encompass all possible isomeric forms. For example, the name propyl includes the two isomers n-propyl and iso-propyl, the name butyl comprises n-butyl, iso-butyl, sec.-butyl and tert.-butyl, the designation pentyl comprises isopentyl, neopentyl, etc. . Optionally, in the aforementioned alkyl groups, if not defined otherwise, one or more hydrogen atoms may be replaced by other radicals. For example, these alkyl groups they can be substituted with the fluoro, chloro, bromo or iodo halogen atoms. Fluoro or chloro substituents are preferred. Eventually all the hydrogen atoms of the alkyl group may also be replaced. As alkyl bridges, unless otherwise indicated, double-branched, branched and unbranched alkyl groups having 4 to 7 carbon atoms, for example, n-butylene bridges, isobutylene bridges, sec-butylene bridges and tert-butylene, pentylene, iso-pentylene, neopentylene, etc. Especially preferred are n-butylene or n-pentylene bridges. In the mentioned alkyl bridges, optionally 1 to 2 C atoms may be replaced by one or more hetaroatoms, selected from the oxygen or sulfur group. As alkenyl groups (also insofar as they are a component of other radicals), branched and unbranched alkenyl groups are considered, with 2 to 10 carbon atoms, preferably 2-6 carbon atoms, especially preferably 2-3 atoms. carbon, provided that they have at least one double bond. For example, there are mentioned: ethenyl, propenyl, butenyl, pentenyl, etc. If not mentioned otherwise, by the designations propenyl, butenyl, etc. All of the possible isomeric forms are encompassed above. For example, the designation butylene encompasses n-butenyl, 1-methylpropenyl, 2-methylpropenyl, 1,1-dimethylethenyl, 1,2-dimethylethenyl, etc. Optionally, in the aforementioned alkenyl groups, if not described otherwise, one or several hydrogen atoms may have been replaced by other radicals. For example, these alkenyl groups may be substituted with the fluoro, chloro, bromo or iodo halogen atoms. The fluoro and chloro substituents are preferred. Eventually, all hydrogen atoms of the alkenyl group can also be replaced. Alkynyl groups (also to the extent that they are components of other radicals) are branched and unbranched alkynyl groups having 2 to 10 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentinyl, hexinyl, etc., preferably ethynyl or propynyl. Alkynyl groups with 2 to 4 carbon atoms are preferred. For example, ethynyl, propynyl, butynyl, pentynyl or hexynyl are mentioned for this purpose. Unless otherwise described, the definitions of propynyl, butynyl, pentynyl and hexynyl embrace all imaginable isomeric forms of the respective radicals. Thus, for example, propynyl covers 1-propynyl and 2-propynyl, butynyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl, etc. Optionally, in the aforementioned alkynyl groups, if not otherwise described, one or more hydrogen atoms may be replaced by other radicals. For example, these alkyl groups may be replaced by halogen atoms fluoro, chloro, bromo or iodo. The fluoro and chloro substituents are preferred. Eventually, all hydrogen atoms of the alkynyl group can also be replaced. As cycloalkyl radicals (also insofar as they are components of other radicals), saturated cycloalkyl radicals with 3-8 carbon atoms are considered, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl or cyclooctyl, preferably cyclopropyl , cyclopentyl or cyclohexyl, wherein each of the aforementioned cycloalkyl radicals optionally carries one or more substituents or it may be fused to a benzene ring. In addition, cycloalkyl radicals can also form, together with monocyclic ring systems, bicyclic, bridged or spirocyclic ring systems. As cycloalkenyl (also insofar as they are a component of other radicals), cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms containing one or two double bonds are considered. For example, there are mentioned for this purpose: cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclooctenyl or cyclooctadienyl. In addition, cycloalkenyl radicals can also form, together with monocyclic ring systems, bicyclic, bridged or spirocyclic ring systems. As cycloalkynyl (also insofar as they are a component of other radicals), cyclic alkyl groups with 5 to 8, preferably 5 or 6 carbon atoms containing one or two triple bonds are considered. For example, there are mentioned: cyclopentinyl, cyclopentadiinyl, cyclohexinyl, cyclohexadinyl, cycloheptinyl, cycloheptadiinyl, cyclooctinyl or cyclooctadiinyl. In addition, cycloalkynyl radicals can also form, together with monocyclic ring systems, bicyclic, bridged or spirocyclic ring systems. As haloalkyl (also insofar as they are a component of other radicals) there are considered alkyl, branched and unbranched groups, with 1 to 6 carbon atoms, in which one or more hydrogen atoms are exchanged with a halogen atom, selected from the group fluoro, chloro or bromo, preferably fluoro and chloro. The term "haloalkyl C-i-4" means alkyl groups, correspondingly branched and unbranched, with 1 to 4 carbon atoms, in which, analogously to as described above, one or more hydrogen atoms are exchanged. C- haloalkyl is preferred. For example, they are mentioned for this: CH2F, CHF2, CF3. The term aryl represents an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, for example phenyl or naphthyl, preferably phenyl, which, insofar as is not otherwise described, can carry, for example, one or more substituents. As heterocycloalkyl radicals are designated, insofar as the definitions are not otherwise described, monocyclic or bicyclic, 5-, 6- or 7-membered, saturated or unsaturated heterocycles, in which up to four C atoms may be replaced by one or more heteroatoms, selected from the group oxygen, nitrogen or sulfur, for example tetrahydrofuran, tetrahydrofuranone, β-butyrolactone, α-pyran, β-pyrano, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepam, oxazine, tetrahydrooxazinyl, isothiazole, pyrazolidin, preferably pyrazolyl, pyrrolidinyl, piperidinyl, piperazinyl or tetrahydrooxazinyl , wherein the heterocycle may be optionally substituted. In this case, the ring can be linked to the molecule through a carbon atom or, if present, through a nitrogen atom. Insofar as it is not mentioned otherwise, a heterocyclic ring can be provided with a keto group. As an example for this, they are mentioned Examples of bicyclic heteroaromatic rings 5-10 membered pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine mentioned, Heteroaryl rings 5-10 membered heteroaryl, or bicyclic unicycles, wherein up to three C atoms may be replaced by one or more heteroatoms selected from the group oxygen, nitrogen or sulfur are designated, where these may contain many double conjugated bonds, which forms an aromatic system. Each of the above-mentioned heterocycles may be optionally further condensed to a benzene ring, preferably benzimidazole. The heteroaryl rings, insofar as not otherwise described, may carry, for example, one or more substituents. The ring can be linked to the molecule through a carbon atom or, if present, through a nitrogen atom. As examples of the five or six membered heterocyclic aromatic compounds are mentioned: Examples of bicyclic heteroaryl rings 5-10 membered pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine mentioned, By spiro-rings expression ( "spiro") heterocyclic spirocyclic rings 5-10 membered can optionally contain one, two or three heteroatoms selected from the group of oxygen, sulfur and nitrogen, in this case the ring may be linked to understood the molecule through a carbon atom or, if present, through a nitrogen atom. Insofar as it is not mentioned otherwise, a spirocyclic ring may be provided with a keto group. As examples for this are mentioned By the term "optionally substituted" is meant, insofar as it is not otherwise indicated, within the scope of the invention, the mentioned group which, if appropriate, is substituted with a radical of low molecular weight. As low molecular weight radicals are understood groups to be considered as chemically convenient, consisting of 1-200 atoms. Preferably, groups of this type have no negative effect on the pharmacological activity of the compounds. For example, groups may include: • linear or branched carbon chains, optionally interrupted by heteroatoms, optionally substituted with rings, heteroatoms or other customary functional groups. • Aromatic or non-aromatic ring systems, consisting of carbon atoms and, eventually, heteroatoms which, again, may be substituted with functional groups. • Several systems aromatic or nonaromatic ring consisting of carbon atoms and optionally heteroatoms, which may be linked to one or more carbon chains, optionally interrupted by heteroatoms, optionally sutituidas with heteroatoms or other common functional groups. As halogen, they are generally referred to as fluoro, chloro, bromo or iodo. The compounds according to the invention can be presented in the form of the individual optical isomers, mixtures of the different enantiomers, diastereomers or racemates, in the form of the tautomers, as well as in the form of the free bases or the corresponding salts by addition of acids with pharmacologically acceptable acids - such as, for example, addition salts with hydrohalic acids, eg hydrochloric or hydrobromic acid, or organic acids such as, for example oxalic, fumaric, diglycolic or methanesulphonic. To the extent that a hyphen "-" opened on one side is used in the structural formula of a substituent, this hyphen is to be understood as a point of connection with the rest of the molecule. The substituent replaces the corresponding radicals R2, R6, etc. Insofar as no open script on the one hand is used in the structural formula of a substituent, the The point of connection with the rest of the molecule is unequivocally deduced from the structural formula itself. The substituent R1 can mean a radical selected from the group consisting of hydrogen, CO-CH3, CO-CH2-R4, CO-CHMe-R4, CO-OR4, CO-SR4, CO-NH2 and CO-NHR4, preferably CO-CH3 and CO-CH2-R4. Particularly preferably, the substituent R1 means CO-CH3. The substituent R 2 may be a radical selected from the group consisting of C 3-6 cycloalkyl, C 1-4 alkyl-C 3-6 cycloalkyl, C 2-6 alkenyl-C 3-6 cycloalkyl, C 2-4 alkynyl-C 3-6 cycloalkyl, C 3-6 cycloalkenyl. , C3-6alkyl-6-cycloalkenyl) C2-4alkenyl-C5-6cycloalkenyl, C2-4alkynyl-C5-6cycloalkenyl, C5-6cycloalkynyl, C5-6alkylalkylC5-6alkenyl, C2-6alkenyl C5-6-cycloalkynyl and C2-4 alkynyl-C5-6 cycloalkynyl; preferably, C 3-6 cycloalkyl, C 1-6 alkyl-C 3-6 cycloalkyl and C 2-4 alkenyl-C 3-6 cycloalkyl; particularly preferred are C 3-6 cycloalkyl, especially cyclopropyl, which may optionally be substituted with one or two of the radicals CH 3, F, OCH 3, OH or NH 2. The substituent R3 may be a radical selected from the group consisting of C6-Ci4 aryl, C6-C6-alkyl, C6-Ci aryl, C2-6 alkenyl-C6-Ci4 aryl, C2-6 alkynyl-C6-Ci4 aryl, C5-heteroaryl C10, Ci-i2 alkyl-C5-C10 heteroaryl, C3-i2 alkenyl-C5-C10 heteroaryl, C3-C2 alkynyl-C5-C10 heteroaryl, C3-6 cycloalkyl, Ci-6 alkyl-C3-6 cycloalkyl, alkenyl C 2-4-C 3-6 cycloalkyl, C 2-4 alkynyl-C 3-6 cycloalkyl, C 5-6 cycloalkenyl, C 1-6 alkylcycloalkenyl, C 2-4 alkenyl Cs-6 cycloalkenyl, C 2-6 alkynyl-cycloalkenyl -6, C5-6 cycloalkynyl, Ci-6-cycloalkynyl C5-6 alkyl, C2-4 alkenyl-C5-6 cycloalkynyl and C2-4 alkynyl-C5-6 cycloalkynyl, preferably C6-Ci4 aryl and C3-6 cycloalkyl, preferably means phenyl and C5-6 cycloalkyl, particularly preferably phenyl, which may optionally be substituted with a radical R5 and up to three radicals R6. R3 can be, preferably, , optionally substituted where n, m, independently of one another, means 1 or 2. The substituent R4 can be a radical, optionally substituted, selected from the group consisting of Ci-4 alkyl, C2-io alkenyl, C2-io alkynyl, C3-6 cycloalkyl-Ci-4 alkyl, C3-6 cycloalkyl-C3 alkenyl- 10, C3-6-C3-10 alkynyl-C3-10 alkynyl, C6-Ci aryl, C6-Ci arylCi-alkyl, C5-C10 heteroaryl, C5-C10 heteroaryl-Ci-4 alkyl and haloalkyl, preferably Ci-3 alkyl, aryl C6-Ci4-C1-4alkyl and haloalkyl, especially preferably methyl, ethyl, n-propyl, i-propyl, c-propyl, phenyl, -CH2-cpropyl, -CH2-phenyl and CF3. The substituent R5 can be a radical selected from the group consisting of CONR8R9, NR8COR9, NR8R9, OR9 and -alkyl Ci-4-CONR8R9; preferably CONR8R9, NR8COR9, NR8R9, OR9 and -CH2-CONR8R9. The substituent R6, same or different, can mean a radical selected from the group consisting of F, Cl, Br, OH, CN, CF3, CHF2 or a possibly substituted radical, selected from the group consisting of O-alkyl Ci-3, O- C3-4 alkenyl, C3-4 O-alkynyl, Ci-3 alkyl, C2-6 alkenyl and C2-3 alkynyl, C3-6 cycloalkylC1-4 alkyl, C3-6 cycloalkylC2-4 alkenyl, C3- cycloalkyl- 6-C 2-4 alkynyl, C 3-6 cycloalkenyl-C 1-4 alkyl, C 3-6 cycloalkenyl-C 3-10 alkenyl, C 3-6 cycloalkenyl-C 2-4 alkynyl, C 6 -aryl-C 1-4 alkyl, C 6 -aryl Ci-C2-4 alkenyl, C6-C4-Ci4 alkynyl-C2- alkynyl, C5-Cio-heteroaryl-Ci-4-alkyl, C5-C2-C2-alkenyl heteroaryl and heteroaryl C5-Ci0-C2-4 alkynyl, preferably meaning F, Cl, Br, Ci-3 alkyl, OH, CN, -O-Ci-3 alkyl, C2-3 alkenyl, C2-3 alkynyl. CF3 and CHF2, particularly preferably F, Cl, Br and CF3 or a radical, optionally substituted, selected from the group consisting of O-Ci-3 alkyl, Ci-3 alkyl, C3-6 cycloalkyl-Ci-4 alkyl and aryl C6-Ci4-Ci-4 alkyl, more preferably F, Cl, CF3, or an optionally substituted O-C1-3alkyl or C1-3alkyl radical. The substituent R7 can mean a radical selected from the group consisting of hydrogen, COR9 and CONR8R9 or a radical, selected from the group consisting of CMO alkyl, C3.10 alkenyl, C3-C0 alkynyl, C4 cycloalkyl-Ci-4alkyl, C3-6 cycloalkylC3-alkenyl, C3-6 cycloalkyl- C3-io alkynyl, C3-6 cycloalkenyl-Ci-4 alkyl, C3-6 cycloalkenyl-C3-0 alkenyl, C3-6 cycloalkenyl-C3-alkynyl, C6-Ci4 aryl, Ci-io-aryl alkyl Ce-C, C2-io-C6-C2-C2-C2-C2-C2-C2-C2-C2-C2-C2-C2-C2-C3-C2; C5-C10 heteroaryl, C5-C10 alkyl d-12-heteroaryl, C3-C2 alkenyl-C5-C10 heteroaryl and C5-C2 alkynyl-C5-C10 heteroaryl, which may optionally be substituted with an R4 radical and with a radical R13. Preferably, R7, the same or different, can be hydrogen, COR9 or CONR8R9, particularly preferably COR9 or CONR8R9. The substituent R8 can be hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-io alkenyl, C3-C0 alkynyl, C3-6 cycloalkylC1-4 alkyl, C3-6 cycloalkylC3-alkenyl , C3-6-alkynyl cycloalkyl 03-10. C3-6 cycloalkenyl-C1-4 alkyl, C3-6 cycloalkenyl-C3-alkenyl, C3-6 cycloalkenyl-C3-10 alkynyl, C6-Ci aryl CrC4 alkyl, C6-Ci4 aryl-C3-alkenyl, and aryl C6-C1-alkynyl C3-i0, C5-Ci0 heteroaryl, C5-Ci0 heteroaryl-C1- alkyl, C5-C6 heteroaryl-C1-4 alkenyl, C5-Ci0 heteroaryl Ci-4 alkynyl, Ci-4 alkyl-O-C2-4 alkyl, Ci-4 alkyl -O-C4-6 alkenyl and C4-6 alkynyl-4-O-alkynyl. Preferably, R 8 can be hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-10 alkyl, alkenyl 03-10, alkynyl 03-10 and alkyl Ci-4-O-C 2-4 alkyl, especially preferably hydrogen or C-MO alkyl. The substituent R 9 can be a radical selected from the group consisting of hydrogen or an optionally substituted radical selected from the group consisting of C 1-12 alkyl, alkenyl 03-12, alkynyl 03-12, cycloalkyl 03-6-alkyl Ci-12 , C3-6-alkenyl cycloalkyl 03.12, C3-6-alkynyl cycloalkyl 03.12, cycloalkenyl 03-6-Ci-4 alkyl, C3-6 cycloalkenyl-C3-alkenyl, C3-6 cycloalkenyl-C3-10 alkynyl, aryl C6- Ci 4 -C 12 alkyl, C 6 -C 4 aryl C 3-2 alkenyl, C 6 -C 14 aryl C 3-12 alkynyl, C 6 -C 14 aryl, C 1 -C 12 alkyl aryl, C 2-12 alkenyl C 6 aryl C1, C2-C2 alkynyl-C6-Ci4 aryl, C5-C10 heteroaryl, C5-Cio-heteroaryl C1.12 alkyl, C5-C5-C2-alkenyl heteroaryl, C3-12 heteroaryl C5-cycloalkynyl, C3- cycloalkyl 8) C3-8 cycloalkenyl, NR11R12-C3-8 cycloalkyl, NR11R12- C4-8 cycloalkenyl and NR11R12-C5-8 cycloalkynyl or optionally substituted C3-8 heterocycloalkyl radical (CH2), which contains at least one NR10 group in the heterocycle of 3 to 8 members ros. Preferably, R 9 can be hydrogen or a radical, optionally substituted, selected from the group consisting of C 1-12 alkyl, C 3-12 alkenyl, C 3-12 alkynyl, C 3-6 cycloalkyl C 1-2 alkyl, C6-C-14 aryl, C6-C14-C12-alkyl, C2-C2-C2-C2-C2-C2-alkenyl, C2-C2-C2-C2-C2-C3-C2-C6-C6-C6-C2-C2-C2-C2-C2-C2-C2-C2-C2-C3-C2-C2-C2 C1-12, C3-12 heteroaryl-alkenyl, C3-12 heteroaryl-alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl and NR 1 R12-C3-8 cycloalkyl or means a C3-8 heterocycloalkyl radical (CH2) q- , optionally substituted, containing at least one NR10 group in the 3- to 8-membered heterocycle. Particularly preferably, R 9 can be hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-12 alkyne, Q.12 alkeny, C 3-12 alkynedib, Ci-12 cycloalkyl Ci-12 alky, C 6 -Ci aryl, Ci alkyl -12-arib C6-C14, alkenyl C6-C14, C6-Ci4 alkynyl, C5-C10 heteroarib, Cs-C-io-alkybi Ci -i2 heteroaryl, Cs-do-alkenib C ^ heteroaryl, C5-Cio-alkynedibynyl Qj.12 heterocycle, cybalquib C8, cycloalkenib and NR 1R12-cycloalkyl Q ^, particularly preferably C-2 alkyne, Q3.12 alkenyb, alkynib-03-12, cycloalkyl C ^ alky Ci-12, C6-C14 ary, Ci -i ary alkyl C6-Ci4, C2 alkenyl -12-C6-C14 alkynyl, C2-C2 alkynyl-C6-C14 arib, C14 cybalquib, cybalkenib, and NR11R12-cybalquib C $%, or means a radical, optionally substituted, selected from the group consisting of the general formulas ( A1) to (A12) (A10) (A11) (A12) The substituents R8 and R9 can together form a 4 to 7 membered saturated or unsaturated alkyl bridge, optionally containing an O atom or a S (0) p group, wherein p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a 5- to 6-membered heterocycle, optionally containing another N atom and optionally substituted with a radical selected from the group consisting of R10, NR11 R12 and NR11 R12alkyl d-4, or a radical where S (O) p > wherein p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a radical, optionally substituted, selected from that consisting of the general formulas (B1) to (B8) wherein z, q, g, d, independently of one another, means 1, 2 or 3. The substituent R 0 may mean a radical selected from the group consisting of hydrogen or a radical, optionally substituted, selected from the group consisting of C 1-10 alkyl, C3-C0 alkenyl, C3-10 alkynyl, C3-7 cycloalkyl-C-1-10 alkyl, C3-7 cycloalkyl-C3-alkenyl, C3-7 cycloalkyl-C3-alkynyl, C3-7 cycloalkyl, Ci-6-cycloalkyl-C3 alkyl -, C2- alkenyl C3-7-cycloalkyl, C2-4 alkynyl-C3- cycloalkyl, tetrahydropyranyl and (NR4) 2CH-C1-6alkyl. Preferably, R10 can mean hydrogen or an optionally substituted radical, selected from the group consisting of alkyl Ci-10, C3-7 cycloalkyl-Ci-10 alkyl, C3-7 cycloalkyl, Ci-6-cycloalkyl C3-7 alkyl, tetrahydropyranyl and (NR) 2CH-alkyl d.10, Substituents R11, R12 may mean, the same or different, hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-10 alkyl, C3-yl alkenyl and C3-yl alkynyl, C3-6 cycloalkyl-Ci-4 alkyl and C3-6 cycloalkyl, preferably C-alkyl -1-10, C3-I0 alkenyl, C5-6 cycloalkyl-C1-4 alkyl and C5-6 cycloalkyl, or R11 and R12 together form an alkyl chain of 4 to 7 members, preferably from 5 to 6 members, which eventually contains a heteroatom. The substituent R13 can mean F, Cl, Br, OH, CN, CF3, CHF2 or alkyl Ci-4-O-. The substituent R14 can mean NR 1R12 or an optionally substituted C3-8- (CH2) q heterocycloalkyl radical containing at least one group NR 0 in the 3- to 8-membered heterocycle, preferably means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12) (A10) (A11) (A12) The substituents R13 and R14 can together form an alkyl bridge, saturated or unsaturated, of 4 to 7 members, preferably an alkyl bridge of 5 to 6 members, which optionally contains an O atom or a S (O) p group, wherein p means 0.1 or 2; preferably 0 or 2. PREPARATION PROCEDURES The compounds of the general formula (I) can be prepared according to the following synthesis ratios (Reactions 1-4), wherein the substituents of the general formula (I) can have the meanings mentioned above. These procedures are to be understood as an explanation of the invention, without limiting it to its object. Reaction 1: VI or the radical R2 can have the meanings mentioned above. R3 'can mean an optionally substituted radical selected from the group consisting of 4-PhCOOMe, 4-PhNO2 and 4-piperidyl, cis / trans-4-alkoxycarbonylcyclohexyl and 4-methoxycarbonyl-methyl-phenyl. And C 1 -C 4 alkyl or -S-C 4 alkyl may be preferably methyl or ethyl. According to reaction 1, a compound of formula II is reacted with a compound of formula III to give a compound of formula IV. Next, the compound of formula IV is reacted with a compound of formula V and cyclized to form a compound of formula VI or la. Reaction 2a: Ib The radicals R2, R6, R8 and R9 can have the meanings indicated above. According to reaction 2a, a compound of the formula Via is reacted by alkali metal hydroxide, preferably LiOH, to give a compound of formula VII. Next, the compound of formula VII is reacted with a compound of formula VIII to give a compound of formula Ib. Reaction 2b: ?? ?? 0 -. 0 - N + ° (Vlb) The radicals R2, R6, R8 and R9 can have the meanings indicated above. According to Reaction 3, a compound of formula Vlb is reduced, by Hb / PdC, in the nitro group, in a compound of formula IX. Next, the compound of the formula IX is reacted with a compound of the formula VIII to give a compound of the formula le or Id. Reaction 4: The radicals R2, R6, R8 and R9 can have the meanings indicated above. According to Reaction 4, a compound of the formula Vlc is reacted to form a compound of the formula le, If or Ig. The new compounds of the general formula (I) can be prepared in analogy to the following Examples. The examples described in the following are to be understood as explaining the invention, but without limiting it. SYNTHESIS OF REAGENTS 1) Compounds of formula III 1.1) IMIDAZOL-1-IL-CICLOPROPIL-METANONE (111.1) 75 g (0.46 mol) of CDI and 30.0 g (0.35 mol) of cyclopropanecarboxylic acid are stirred for 20 h at RT. Then, the reaction mixture is washed twice with 200 mL of common salt solution, the organic phase is dried and the solvent is removed in vacuo. Yield: 45.5 g (96%). 1.2) Cyclopentyimidazol-1-yl-methanone (III.2) 17. 70 g (155.07 mmol) of cyclopentanecarboxylic acid are placed in 350 mL of dichloromethane, and 30.00 g (181.00 mmol) of CDI are added in portions. The reaction mixture is stirred for 3 hours at room temperature, then cooled to 0 ° C and a little ice is added. Stirring is continued for 0.1 hour, and then it is extracted with half-saturated sodium chloride solution. The organic phase is dried and concentrated by evaporation to dryness. Yield: 25.00 g (98%). The following compounds are prepared analogously: 1.3) lmidazol-1-yl- (1-methyl-cyclopropyl) -methanone (III.3) .50 g (0.105 mol) of 1-methylcyclopropanecarboxylic acid and 22.00 g (0.136 mol) of CDI are used. Yield: 16.10 g (94%) 1.4) Cyclobutyl-imidazol-1-yl-methanone (III.4) .00 g (200 mmol) of cyclobutanecarboxylic acid and 37.00 g (224 mmol) of CDI are used. Yield: 29.10 g (97%) 2) Compounds of the formula V 2.1) 3-Chloro-4-hydrazino-benzoic acid methyl ester (V.1) 31. 99 g (0.172 mol) of methyl 4-amino-3-chlorobenzoate are suspended in 160 mL conc. Hydrochloric acid. and cooled to -10 ° C. A solution based on 11.98 g (0.174 mol) of sodium nitrite and 160 mL of water is added dropwise at -5 ° C. In the resulting solution, 170.98 g (0.759 mol) of tin (II) chloride in 140 mL of hydrochloric acid are added dropwise. It is a thick precipitate. The reaction mixture is frozen over night. After thawing, the suspension is made basic with 10 molar soda lye. After the addition of dichloromethane, the product is separated and separated with the organic phase. This is washed with water, dried and concentrated by evaporation to dryness. The residue is purified by chromatography. Yield: 18.3 g (53%). The following compounds are prepared analogously: 2.2) (3-Chloro-4-hydrazino-phenyl) -acetic acid methyl ester (V.2) . 00 g (25 mmol) of methyl ester of (4-amino-3-chlorophenyl) -acetic acid, 80 mL of conc. Hydrochloric acid, 1.90 g (28 mmol) of sodium nitrite and 22.60 g (100 mmol) of tin chloride- (ll) dihydrate are used in 30 mL of hydrochloric acid. Yield: 2.33 g (43%). 2.3) 2-Chloro-4-hydrazino-benzoic acid methyl ester (V.3) 49. 08 g (0.221 mol) of 4-amino-2-chloro-methyl benzoate hydrochloride, 250 mL of conc. Hydrochloric acid, 18.23 g (0.264 mol) of sodium nitrite and 199.12 g (0.883 mol) of tin chloride- (ll) Dihydrate are used in 250 mL of conc. hydrochloric acid. Yield after crystallization from isopropanol: 24.7 g (56%). 2.4) 4-Hydrazino-2-methoxy-benzoic acid methyl ester (V.4) . 00 g (0.138 mol) of methyl 4-amino-2-methoxybenzoate are suspended in 124 mL conc. Hydrochloric acid. and they are cooled to 2o C. Slowly, a solution based on 11.42 g (0.166 mol) of sodium nitrite in 124 mL of water is added dropwise, and then it is stirred for 1 hour under cooling in an ice bath. A solution based on 60.45 g is available (0.318 mol) of sodium pyrosulfite in 248 mL of water (adjusted to pH 6.5 with sodium hydroxide) and the cooled diazonium solution is slowly added dropwise. With this, the pH value is maintained between 6.3 and 6.5. The reaction mixture is stirred for 4 hours at reflux, then it is added to 260 mL of conc. Hydrochloric acid. and left to stand for 16 hours at room temperature. The solution is then basified and extracted with tetrahydrofuran and ethyl acetate. The organic phase is dried and concentrated by evaporation to dryness. The residue is crystallized from isopropanol and then the hydrochloride is precipitated. Yield: 9.72 g (30%). 2.5) 2-Chloro-4-nitro-phenyl-hydrazine hydrochloride (V.5) . 00 g (0.140 mol) of 2-chloro-4-nitro-fluorobenzene and 7.00 g (0.140 mol) of hydrazine hydrate are placed in 45 mL of 1-methyl-2-pyrrolidone and stirred for 3.5 hours at 65 ° C. After cooling, the reaction mixture is combined with water and the resulting precipitate is filtered off with suction. The wet crystals are recrystallized from isopropanol and then the hydrochloride is precipitated. Yield: 11.4 g (36%). 2.6) 2.6.1) 4- (tert-butoxycarbonyl-hydrazone) -piperidine-1-butyl tert-butyl ester . 00 g (50.19 mmol) of BOC-piperidone and 6.63 g (50.19 mmol) of BOC-hydrazine is stirred at reflux with 20 g of molecular sieve in 250 mL of n-hexane for 4 hours. It is then concentrated by evaporation and the residue is stirred for 2 hours in acetonitrile, filtered off with suction over diatomaceous earth and concentrated by evaporation. Yield: 8.00 g (51%). 2.6.2) Piperidin-4-yl-hydrazine (V.6) 8. 00 g (25.53 mmol) of 4- (tert-butoxycarbonyl-hydrazono) -piperidine-1-carboxylic acid tert-butyl ester are stirred in 26.00 mL (26 mmol) of borane-tetrahydrofuran complex (1 molar) for 24 hours. hours at room temperature, then mixed with 4 molar hydrochloric acid in dioxane and stirred for 24 hours at room temperature. The reaction mixture is concentrated in vacuo, crystallized and filtered with suction. The crude product is mixed with water, saturated with sodium chloride and extracted with tetrahydrofuran. The aqueous phase is concentrated by evaporation, the residue is triturated with tetrahydrofuran, filtered and concentrated by evaporation. Precipitate the hydrochloride. Yield: 4.30 g (90%). 2.7) 2.7.1) Cis / trans-4- (N'-tert-butoxycarbonyl-hydrazino) -cyclohexanecarboxylic acid ethyl ester . 50 g (61.69 mmol) of 4-oxo-cyclohexanecarboxylic acid ethyl ester are placed in 200 mL of hexane and 8.15 g are added. (61.69 mmol) of tere-butyl carbazate. It is stirred for 4 hours at reflux, cooled to room temperature and mixed with 70 mL (70 mmol) of borane-tetrahydrofuran complex (1 molar). The reaction mixture is stirred for 16 hours at room temperature. Then, 5 mL of water are added and concentrated by evaporation. The residue is mixed with ethyl acetate and magnesium sulfate is added. The suspension is filtered with suction and the filtrate is concentrated by evaporation to dryness. The residue is separated by chromatography on a 2.5 I silica gel column (cyclohexane / ethyl acetate). Yield: 6.97 g (40%) of cis compound and 7.32 g (42%) of trans compound. 2.7.2) Ethyl ester of cis-4-hydrazino-cyclohexanecarboxylic acid (V.7) 6. 90 g (24.10 mmol) of cis-4- (N'-tert-butoxycarbonyl-hydrazino) -cyclohexanecarboxylic acid ethyl ester are dissolved in 75 mL of dioxane and 50 mL of hydrochloric acid solution in dioxane (4 molar) are added. . The reaction mixture is stirred for 16 hours at 40 ° C. After cooling, diethyl ether is added, the precipitate is filtered off with suction, washed with diethyl ether and dried. Yield: 5.06 g (94%). 2.8) Ethyl ester of trans-4-hydrazino-cyclohexanecarboxylic acid (V.8) 7.30 g (25.49 mmol) of trans-4- (N'-tert.-butoxycarbonyl-hydrazino) -cyclohexanecarboxylic acid ethyl ester are used. Yield: 5.60 g (99%). 3) Compounds of the formula VIII 3.1) cis- (4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester . 00 g (0.0467 mol) of tert-butyl-cis-4-aminocciohexane carbamate, 12.10 g (0.0560 mol) of 1,4-dibromobutane and 25.00 g (0.250 mol) of potassium hydrogen carbonate are disposed in 400 ml_ of dimethylformamide and then stirred for 24 hours at room temperature. It is then concentrated by evaporation and the residue is extracted with diethyl ether and water. The organic phase is dried and concentrated by evaporation to dryness. The product, still impure, precipitates in the form of salt, crystallizes in acetonitrile and is released again. Yield: 6.0 g (48%). The following compound is prepared analogously: 3.2) 3.2.1) Cs- (4-pyridin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester .00 g (47 mmol) of tert-butyl-cis-4-aminocyclohexane carbamate, 7.63 ml (56 mmol) of 1,5-dibromopentane and 23.36 g (233.31) are employed. mmol) of potassium hydrogen carbonate in 450 ml_ of dimethylformamide. Yield: 14.23 g (100%) The following compound is prepared analogously: 3.2.2) cis-4-piperidin-1-yl-cyclohexyl amine dihydrochloride 7.12 g (25 mmol) of cis-4-piperidin-1-yl-cyclohexylcarbamic acid tert-butyl ester and 201.54 ml_ (202 mmol) of 1 molar ethereal hydrochloric acid are used. Yield: 8.44 g (100%). 3.3) 3.3.1) Methyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester 4. 00 g (0.0149 mol) of tert-butyl acid ester (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid are placed in 40 ml_ of dimethylformamide and 0.660 g (0.0165 mol) of sodium hydride are added ( to 60% in oil). After the foaming is complete, 2.32 g (0.0163 mol) of methyl iodide are added and stirred at room temperature. The reaction mixture is washed with water and extracted with ethyl acetate, the organic phase is dried and concentrated by evaporation to dryness. The residue precipitates in the form of oxalate. Yield: 1.58 g (38%). 3.3.2) Methyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -amine 1. 70 g (6 mmol) of methyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester and 20 ml_ of trifluoroacetic acid are placed in 100 dichloromethane and then stirred for 4 h the room temperature. Then, the reaction mixture is concentrated by evaporation and the residue is precipitated as a salt. Yield: 1.45 g (94%). 3.4) Cs- (4-cyclopropyl-methylamino-cyclohex-1-D-carbamic acid tert-butyl ester) (46.6 mmol) of tert-butyl-cis-4-aminocyclohexane carbamate and 3.5 ml_ (46.6 mmol) of cyclopropylcarboxaldehyde are stirred in 500 ml of dioxane for 3 h at room temperature. Then, 20.8 g (93.3 mmol) of sodium triacetoxyborohydride are added and stirring is continued overnight, mixed with 200 ml_ of 5% potassium carbonate solution and stirred for 1 h. The phases are separated and the aqueous phase is extracted with stirring with methylene chloride. The phases org. they are combined and extracted once with agitation with water, then dried and concentrated. The crude product is applied on silica gel and separated on a column of silica gel. The appropriate fractions are pooled, concentrated and mixed in 500 mL of dichloroethane with 3.8 mL of 37% formalin solution and stirred for 3 h at room temperature. Then, 10 g (48 mmol) of sodium triacetoxyborohydride are added and stirring is continued overnight. To the next day, it is extracted with stirring with 5% potassium carbonate solution, the phases are separated and the org. it is extracted with stirring with saturated sodium chloride solution. The org phase it dries and concentrates. Yield: 6.49 g (40.3%) 3.5) 3.5.1) Ethyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester Starting from 5.00 g (0.0139 mol) of tert-butyl acid ester (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid, the base is released. 0.600 g (0.0150 mmol) of sodium hydride (60% in oil) are placed in 15 mL of dimethylacetamide and heated to 40 ° C. 25% of a solution of a free base in 15 mL of water is added dropwise. dimethylacetamide. Then it is heated to 55 ° -60 ° C and the remaining solution is added dropwise. The reaction mixture is stirred for 1 hour at this temperature and for 1 hour at room temperature. After cooling to -10 ° C, 1.20 mL (0.0148 mol) of ethyl iodide are added and then stirred for 16 hours at room temperature. The reaction mixture is combined with water and extracted with ethyl acetate. The combined organic phases are dried and concentrated by evaporation to dryness. The residue is purified by chromatography. Yield: 0.170 g (4%). 3.5.2) Ethyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -amine dichloride OC 170 mg (0.573 mmol) of ethyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -carbamic acid tert-butyl ester are dissolved in 5 ml of methanolic hydrochloric acid (1.25 molar) and stirred for 16 hours at room temperature. Methanol is concentrated by evaporation in a vacuum and the residue is mixed with acetone. The resulting precipitate is filtered with suction, washed and dried. Yield: 100 mg (65%). 4.) For the reaction of the compound of the formula (Vlc) to give the compound of the formula (If) the following compounds can be prepared: 4.1) 4.1.1) Ethyl 1-cyclopentyl-piperidin-4-ethyl ester -carboxylic 22. 90 g (145.67 mmol) of ethyl ester of piperidine-4-carboxylic acid and 13.48 g of cyclopentanone are placed in 400 ml_ of tetrahydrofuran, and 0.750 g of p-toluenesulfonic acid and 12.50 ml_ (218.50 mmol) of acid are added. glacial acetic The reaction mixture is stirred for 0.5 hour at room temperature and then 42.25 g (189.36 mmol) of sodium acetoxyborohydride are added in portions. It is stirred for 16 h at room temperature and then concentrated by evaporation. The residue is extracted with dichloromethane and sodium carbonate solution. The organic phase is dried and concentrated by evaporation to dryness. The aqueous phase is adjusted to pH 8 and extracted with chloroform. The organic phase is dried and concentrated by evaporation to dryness. The two substances meet. Performance: 39.70 g (100%) 4.1.2) 1-Cyclopentyl-p-peridin-4-carboxylic acid hydrochloride . 00 g (133.140 mmol) of ethyl ester of 1-cyclopentyl-piperidine-4-carboxylic acid and 150 mL of conc. Hydrochloric acid. they are placed in 150 mL of water and then stirred for 16 hours at 100 ° C. The reaction mixture is concentrated in vacuo and a precipitate results. This is filtered with suction and dried. Yield: 12.1 g (39%) 4.2) 4.2.1) 1-propyl-piperidine-4-carboxylic acid ethyl ester . 19 g (64.82 mmol) of ethyl ester of piperidine-4-carboxylic acid and 4.80 mL (66.45 mmol) of propionaldehyde are placed in 150 mL of ethanol and 6.55 mL (64.84 mmol) of borane-pyridine complex are added. The reaction mixture is stirred for 4 h at room temperature and then concentrated by evaporation. The residue is extracted with dichloromethane and water and the organic phase is dried and concentrated to dryness. The residue is purified by chromatography. Yield: 1.90 g (15%). 4.2.2) 1-propyl-piperidine-4-carboxylic acid 1. 90 g (9.53 mmol) of 1-propyl-piperidine-4-carboxylic acid ethyl ester and 30.00 mL (30 mmol) of 1-molar sodium hydroxide solution are stirred in 10 mL of methanol for 2 h at room temperature. The solution is then adjusted to pH 6 with 1 molar hydrochloric acid and concentrated by evaporation. The residue is dissolved in methanol and filtered on silica gel. The filtrate is concentrated by evaporation and extracted with stirring with methanol. Yield: 1.70 g (100%). For the reaction of the compound of the formula (IX) to give the compound of the formula (Id) the following compounds can be prepared: 4.3) 1-Cyclopentyl-piperidine-4-carbonyl chloride 65 mg (0.278 mmol) of 1-cyclopentyl-piperidine-4-carboxylic acid hydrochloride and 100 pL (1.38 mmol) of thionyl chloride are placed in 8 mL of toluene and 50 pL of dimethylformamide and stirred for 3 h under reflux. It is then concentrated by evaporation, mixed with toluene and concentrated again by evaporation. It continues to react directly. The following compound is prepared analogously: 4.4) 1-propyl-pipehdin-4-carbonyl chloride 240 mg (1.40 mmol) of 1-propyl-piperidine-4-carboxylic acid and 2 ml_ (27.57 mmol) of thionyl chloride are used. Yield: 270 mg (85%). SYNTHESIS OF INTERMEDIATE COMPOUNDS 5) Compounds of formula IV 5.1) N- (6-cyclopopilcarbonyl-7-oxo-4,5,6,7-tetrahydrobenzothiazol-2-yl) -acetamide 34. 0 g (0.16 mol) of N- (7-oxo-4,5,6,7-tetrahydrobenzothiazol-2-yl) -acetamide are placed in 3.5 L of THF, cooled to -30 ° C and drop added to drop 500 ml_ of a 1 molar solution of LHMDS at max. -20 ° C. After the addn is complete, stir for 4 h at -30 ° C to -20 ° C. Then, 45.0 g (0.33 mol) of imidazol-1-yl-cyclopropyl-methanone, dissolved in 50 ml_ of THF are added dropwise as max. -20 ° C. It is allowed to arrive at RT overnight, and then HCl gas is introduced until pH 3 is reached. The resulting yellow suspension is added to 1500 mL of phosphate buffer, the org. it is separated and the aqueous phase is extracted once with ethyl acetate. The phases org. they are dried over MgSO 4 and concentrated by evaporation in vacuo. The oily residue crystallized overnight and, after the addn of some acetonitrile, the product was filtered off with suction and dried. Yield: 33.2 g (74%) 5.2) N- (6-cyclobutanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazole-2-) il) -acetamide (IV.2) . 00 g (93.22 mmol) of N- (7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide are placed in 400 ml_ of tetrahydrofuran and cooled to -70 ° C. Slowly add 280 ml_ (280 mmol) of lithium bi- (trimethylsilyl) -amide (LHMDS) and then stir for 3 hours at -60 ° to -70 ° C. 18.00 g (120 mmol) of cyclobutyl Imidazol-1-yl-methanone are added dropwise in 100 ml_ of tetrahydrofuran and the reaction mixture is allowed to reach room temperature in the space of 16 hours. It is then acidified, under cooling, with a solution of 4 molar hydrochloric acid in dioxane, phosphate buffer is added and the mixture is adjusted to pH 6.5 with sodium carbonate solution. After the addn of ethyl acetate and sodium chloride solution, it is extracted. The organic phase is dried and concentrated by evaporation to dryness. 13.30 g (66%). The following compounds are prepared analogously: 5.3) N- [6- (1-methyl-cyclopropanecarbonyl) -7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-n-acetamide (IV.3 ) 12.00 g (57.07 mmol) of N- (7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide, 172 mL (172 mmol) of LHMDS and 16.10 g (98.63 mmol) are used. of imidazol-1-yl- (1-methyl-cyclopropyl) -methanone. Yield: 24.70 g (100%). HPLC: method B, RT = 1.59 min, MH + = 293 5.4) N- (6-cyclopentanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) - acetamide (IV.4) .00 g (93.22 mmol) of N- (7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide, 280.00 ml_ (280.00 mmol) of LHMDS and 25.00 g (152.25 mmol) are used. of cyclopentyl-imidazol-1-yl-methanone. Yield: 21.56 g (53%). 6) Compounds of the formula Via 6.1) 4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,44benzon .2-dltiazole-1-i0-3] methyl ester -chloro-benzoic (Vla.1) 2. 00 g (0.00719 mol) of N- (6-cyclopropylcarbonyl-7-oxo-4,5,6,7-tetrahydrobenzothiazol-2-yl) -acetamide are placed in 50 ml_ of glacial acetic acid and 1.75 g (0.00872) are added. mol) of 3-chloro-4-hydrazino-benzoic acid methyl ester. The retraction mixture is stirred for 90 h at room temperature. The glacial acetic acid is then concentrated by evaporation in a vacuum and the residue is extracted with 5% potassium carbonate solution and ethyl acetate. The combined organic phases are dried, concentrated by evaporation to dryness and then crystallized from acetonitrile. The mixture of isomers is separated by chromatography. Yield: 1.61 g (51%). In an analogous manner, the following compounds are prepared: 6. 2) 4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolor-3 ', 4': methyl ester, 3,4-benzoic acid, 2-d1-tiazol-1-in-2-chloro-benzoic acid (Vla.2) 1.50 g (0.539 mol) of N- [1- (2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H -pyrazolo [3,4 '3,4] benzo [1, 2 d] thiazol-7-yl] -acetamide, 30 mL of glacial acetic acid and 1 mL of conc. hydrochloric acid. and 1.20 g (0.598 mol) of 2-chloro-4-hydrazino-benzoic acid methyl ester. Yield: 1.22 g (51%). 6.3) 4- (7-Acetylamino) -3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3.41benzoM.2-dltiazol-1-yl) -2-methoxy methyl ester -benzoic (Vla.3) 4.00 g (0.0144 mol) of N- (6-cyclopropylcarbonyl-7-oxo-4,5,6,7-tetrahydrobenzothiazol-2-yl) -acetamide, 3.40 g (0.0146 mol) of 4-methyl ester are used. Hydrazino-2-methoxy-benzoic acid. Yield: 4.70 g (75%) 6.4) 4-i7-Acetylamino-3- (1-methyl-cyclopropyl) -4,5-dihydro-pyrrazolor3 ', 4': 3, 4-benzoM2-d1-thiazole methyl ester -1,5-chloro-benzoic acid (Vla.4) they employ 8.70 g (20.83 mmol) of N- [6- (1-methyl-cyclopropanecarbonyl) -7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl] -acetamide, 7.00 g (34.89 g. mmol) of 3-chloro-4-hydrazino-benzoic acid methyl ester and 100 mL of glacial acetic acid. Yield: 1.50 g (16%), HPLC-MS: method A, RT = 3.22 min, MH + = 457/459. 6.5) 4- (7-Acetylamino-3-cyclobutyl-4,5-dihydro-pyrazolof3 ', 4': 3,4-benzof-1,2-dltiazol-1-yl) -3-chloro-benzoic acid methyl ester (Vla. 5) 13.30 g (30 mmol) of N- (6-cyclobutanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide, 9.13 g (45 mmol) of methyl ester of acid are used. 3-Chloro-4-hydrazino-benzoic acid and 150 mL of glacial acetic acid.

Yield: 7.00 g (51%), HPLC-MS: method B, RT = 2.15 min, MH + = 457. 7) Compounds of the formula VI b 7.1) N-Í1 - (2-chloro-4-nitro-phen) n-3-cyclopropyl-4,5-dihydro-1 H-pyrazolor3'.4 ': 3.41benzo-ri .2-dltiazol-7-ill-acetamide (Vlb.1) 9.00 g (0.0323 mol) of N- (6-cyclopropylcarbonyl-7-oxo-4,5,6,7-tetrahydrobenzothiazole-2-yl) -acetamide, 7.24 g (0.0323 mol) of hyd are employed. Rhodium chloride of (2-chloro-4-nitro-phenyl) -hydrazine and 100 mL of glacial acetic acid. Yield: 10.24 g (74%). HPLC-MS: method B, RT = 3.09 min, MH + = 429/431. 8) Compounds of formula VII 8.1) 4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolof3 ', 4': 3,41benzof1, 2-dltiazol-1-yl) - 3-chloro-benzoic 1. 60 g (0.00361 mol) of 4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazole methyl ester) 1-yl) -3-chloro-benzoic acid are placed in 40 mL of tetrahydrofuran and a solution based on 0.500 g (0.0209 mol) of lithium hydroxide in 5 mL of water is added. The reaction mixture is stirred for 16 h at room temperature and then acidified with glacial acetic acid. The solvent is concentrated by evaporation in a vacuum and the residue is mixed with water. The precipitated crystals are filtered with suction and washed with water. Yield: 1.51 g (98%).

The following compounds are prepared analogously: 8.2) 4- (7-Acetylamino-3-cyclopropyl-4,5-d, 4-pyrazolor3'.4 ': 3.4-benzof1 acid. 2-d1-thiazol-1-yl) -2-chloro-benzoyl 1.20 g (0.00271 mol) of 4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] methyl ester are used. thiazol-1-yl) -2-chloro-benzoic acid and 0.500 g (0.0209 mol) of lithium hydroxide. Yield: 1.12 g (96%). 8.3) 4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolof3 ', 4': 3,41-benzof1,2-dithiazol-1-yl) -2-methoxy-benzoic acid 4.70 g (0.0108 mol) of 4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1, 2-d] methyl ester are used. thiazol-1-yl) -2-methoxy-benzoic acid. Yield: 4.38 g (96%). 8.4) 4- [7-Acetyl-lane-3- (1-methyl-cyclopropyl) -4,5-dihydro-pyrazolof3 ', 4': 3,41ben-zo [1,2-d] t azol-1-β-3-chloro-benzoic acid 1.50 g (3.28 mmol) of 4- [7-acetylamino-3- (1-methyl-cyclopropyl) -4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzoic acid methyl ester are used. 1,2-d] thiazol-1-yl) -3-chloro-benzoic acid in 15 mL of dioxane and 0.245 g (10.23 mmol) of lithium hydroxide in 1 mL of water. Yield: 1.45 g (100%), HPLC-MS: method B, RT = 1.93 min, MH + = 443/45 8.5) 4- (7-Acetylamino-3-cyclobutyl-4,5-dihydro-pyrazolo [3 ' , 4 ': 3,41-benzoyl-1,2-dithiazol-1-yl) -3-chloro-benzoic acid 6.70 g (15 mmol) of 4- (7-acetylamino-3-cyclobutyl) -4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] methyl ester are used. ] thiazol-1-yl) -3-chloro-benzoic acid in 100 mL of dioxane and 1.20 g (49.10 mmol) of lithium hydroxide in 10 mL of water. Yield: 5.80 g (89%), HPLC-MS: method A, RT = 3.0 min, MH + = 443. 9) Compounds of the formula Vlc 9.1) N- (3-cyclopropyl-1-piperidin-4-yl-4.5) -dihydro-1 H-pyrazolor3'.4 ': 3,41benzon .2-dlthiazol-7-yl) -acetamide (Vlc.1) 6. 12 g (21.99 mmol) of N- (6-cyclopropanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide and 4.30 g (22.86 mmol) of piperidine 4-yl-hydrazine is stirred in 50 mL of glacial acetic acid for 48 hours at 50 ° C. It is then concentrated by evaporation and the residue is crystallized from acetonitrile. Yield: 3.00 g (38%). 9.2) N- (3-cyclopropyl-1-G1 - (piperidine-4-carbonyl) -piperidin-4-ill-4,5-dihydro-1 H-pyrazolor3 ', 4': 3.41benzoM, 2-d1-thiazole-7 -yl) -acetamide (Vlc.2) 1. 00 g (1.76 mmol) of 4- [4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo] tert-butyl ester [1] 2-d] thiazol-1-yl) -piperidine-1-carbonyl] -piperidine-1-carboxylic acid and 20 mL of trifluoroacetic acid are stirred in 200 mL of dichloromethane for 24 hours at room temperature. The reaction mixture is concentrated by evaporation and the residue is made basic with sodium hydroxide solution. The precipitate is filtered with suction and dried. Yield: 0.800 g (97%).

) Synthesis of other intermediate compounds 10.1) Methyl ester of r4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrrazolo [3 ', 4': 3,41-benzoyl-1,2-d-thiazole-1-acid] il) -3-chloro-phenyl-1-acetic 2.70 g (10 mmol) of N- (6-cyclopropanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide, 2.29 g (11 mmol) of methyl ester of acid are used. (3-chloro-4-hydrazino-benzoic acid) and 36 mL of glacial acetic acid. Yield: 2.71 g (61%). 10.2) 4-β4- (7-Acetylamino-3-cyclopropyl) -4,5-dihydro-pyrazoloyl-3 ', 4'-tert-butyl ester: 3,41-benzoH, 2-d-thiazole-1-yl-piperidine-1 - carbonill-piperidine-1-carboxylic 1. 00 g (2.80 mmol) of N- (3-cyclopropyl-1-piperidin-4-yl-4,5-dihydro-1 H-pyrazolo [3 \ 4 3 ^] benzo [1,2-d] thiazole-7 -yl) -acetamide, 0.700 g (3.05 mmol) of mono-tert-butyl ester of piperidine-1,4-dicarboxylic acid, 0.980 g (3.05 g) mmol) of O- (1 H-benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium tetrafluoroborate (TBTU) and 3 mL of triethylamine are stirred in 100 mL of dichloromethane for 24 hours at the room temperature. It is then extracted with 10% potassium hydrogen carbonate and the organic phase is dried and concentrated by evaporation to dryness. The residue is crystallized from ethyl acetate. Yield: 1.00 g (63%). 10.3) .4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,41-benzo [1,2-d-thiazol-1-yl] -3-chloro-phenyl-acetic acid] 2.70 g (6 mmol) of 4- [7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [, 2-d] thiazole methyl ester are used. -1-yl) -3-chloro-phenyl] -acetic acid in 95 mL of tetrahydrofuran and 0.764 g (31.91 mmol) of lithium hydroxide in 10 mL of water. Yield: 2.11 g (61%). 10.4) cis-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolof3 ', 4': 3,4lbenzon, 2-dltiazol-1-yl) -cyclohexanecarboxylic acid 300 mg (0.700 mmol) of cis-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1, 2-] ethyl ester are used. d] thiazol-1-yl) -cyclohexanecarboxylic acid in 10 mL of tetrahydrofuran and 150 mg (6.26 mmol) of lithium hydroxide in 2 mL of water. Yield: 262 mg (94%). 10.5) trans-4- (7-Acetylamino-3-cyclopropyl-415-dihydro-pyrrazolo [3 ', 4': 3,41-benzo-f-1, 2-d-thiazol-1-yl) -cyclohexanecarboxylic acid 500 mg (1.17 mmol) of trans-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2] -ethyl ethyl ester are used. d] thiazol-1 - ??) - cyclohexanecarboxylic acid in 30 mL of tetrahydrofuran and 250 mg (10.44 mmol) of lithium hydroxide in 10 mL of water. Yield: 457 mg (98%). 10.6) 4- (7-Acetylamino-3-cyclopropyl-4,5-dydro-pyrazolo [3 ', 4': 3,41benzof1.2-d] thiazol-1-yl) -3- chloro-phenyl-boric 500 mg (0.979 mmol) of N- [1- (2-chloro-4-iodo-phenyl) -3-cyclopropyl-4,5-dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1, 2-d] thiazol-7-yl] -acetamide are dissolved, under a nitrogen atmosphere and under absolutely anhydrous conditions, in 3 mL of tetrahydrofuran and 41.49 mg (1.00 mmol) of lithium chloride are added. Cool to -30 ° C and add 0.489 mL (0.979 mmol) of isopropylmagnesium chloride in tetrahydrofuran (1 molar) and 0.326 mL (0.979 mmol) of methylmagnesium chloride in tetrahydrofuran (3 molar). The reaction mixture is stirred for 1.5 hours at -10 ° C. Then, 0.51 mL (4.89 mmol) of trimethyl borate is added dropwise at -20 ° C. It is stirred for 16 hours at room temperature and then it is mixed with 2.5 mL of hydrochloric acid (2 molar). Water is added to the resulting solution and the tetrahydrofuran is concentrated by evaporation in a vacuum. The resulting precipitate is filtered with suction and purified by chromatography. The product is crystallized from ethyl acetate / petroleum ether. Yield: 192.6 mg (46%). 10.7) Ethyl ester of cis-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolor3 ', 4': 3,4-benzof1,2-dlt-azozol-1-yl) -cyclohexanecarboxylic acid ester 3. 00 g (10.78 mmol) of N- (6-cyclopropanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide are placed in 100 mL of glacial acetic acid, 2.70 g are added. (12.12 mmol) of cis-4-hydrazino-cyclohexanecarboxylic acid ethyl ester and stirred for 72 h at 80 ° C. Then, it is concentrated by evaporation and the residue is extracted with ethyl acetate and semi-concentrated ammonia. The organic phase is dried and concentrated by evaporation to dryness. The residue is purified by chromatography (RP-HPLC). Performance: 0. 317 g (7%), HPLC-MS: method A, RT = 3.06 min, MH + = 429. 10.8) Ethyl ester of trans-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolof3 'acid) , 4 ': 3,41benzori, 2-dlthiazol-1-yl) -cyclohexanecarboxylic acid 1. 95 g (7.01 mmol) of N- (6-cyclopropanecarbonyl-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl) -acetamide and 1.60 g (7.18 mmol) of ethyl ester of trans- 4-Hydrazino-cyclohexanecarboxylic acid is stirred in 100 ml_ of ethanol for 144 hours at 65 ° C. Then, the reaction mixture is concentrated by evaporation and the residue is mixed with ethyl acetate. The insoluble material is filtered with suction, and the filtrate is extracted first with water and then with 5% potassium carbonate solution. The organic phase is dried and concentrated by evaporation to dryness. The residue is purified by chromatography. Yield: 365 mg (12%). SYNTHESIS OF FORMULA COMPOUNDS (I) For the characterization of the compounds of formula (I) the following HPLC-MS methods were used: Waters ZMD, HPLC Alliance 2690/2695, Waters 2700 Autosampler, Detector of the dispoisicon of Waters 996/2996 diodes (wavelength range 210-400 nm). Stationary phase (column temperature: constant at 25 ° C): Method A: XTerra® column, MS Ci8 2.5 μ? T ?, 4.6 mm x 30 mm.

Method B: Merck Chromolith ™ SpeedROD RP-18e column, 4.6 mm x 50 mm. Method C: Waters ZQ2000, Gilson 215 autosampler, HP1100 HPLC + diode array detector (wavelength range 210-500 nm); XTerra® column, MS C-i8 3.5 μ? t ?, 4.6 mm x 50 mm. Mobile phase: L1: water with 0.10% TFA; L2: acetonitrile with 0.10% TFA Flow: Method A: 1.00 mL / min Method B: 2.00 mL / min Method C: 1.00 mL / min Time (min)% A% B 0.0 95 5 0.1 95 5 3.1 2 98 4.5 2 98 5.0 95 5 The symbol X2,? ß, etc. in the structural formula of the substituents, used in Tables A to G, it is to be understood as the point of attachment to the rest of the molecule. The substituent replaces the corresponding radicals R2, R6, etc. Example 1: N-M - (2-chloro-phenin-3-cyclopropyl-4,5-dihydro-1 H-pyrazoloyl-3 ', 4': 3,41-benzoM, 2-dltiazol-7-ill-acetamide 100 mg (0.359 mmol) of N- (6-cyclopropylcarbonyl-7-oxo-4,5,6,7-tetrahydrobenzothiazol-2-yl) -acetamide are placed in 5 mL of glacial acetic acid, 75 mg (0.419 mmol) of o-chlorophenylhydrazine hydrochloride are added, and then it is stirred for 90 h at room temperature. Then, the reaction mixture is combined with water and crystallized. The precipitated crystals are filtered with suction and recirstalized in acetonitrile. Yield: 86 mg 62%). HPLC-MS: method C, RT = 3.91 min, MH + = 385. The following compounds are prepared analogously: Table A Ex. R2 R6 Method RT M + H A [min] 1 H C 3.88 351 x2 - ^ Ex. R2 R6 Method RT M + H A [min] 2 A 3.05 419 F F 3 C 3.85 365 X6 ^ CH3 4 C 3.91 429 A 3.05 399/01 6 A 3.18 399 Ex. R2 R6 Method RT M + H A [min] 7 A 3.24 412 Xe-CI Example 2: Nf 1 - (4-amino-2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 Hp -razolor 3 ', 4': 3,41-benzoH, 2-d-thiazole-7-ill -acetamida .24 g (0.0238 mol) of N- [1- (2-chloro-4-nitro-phenyl) -3-cyclopropyl-4,5-dihydro-H-pyrazolo [3 ', 4': 3,4] are placed. benzo [1,2-d] thiazol-7-yl] -acetamide at 70 ° C, dissolved in 150 ml_ of glacial acetic acid. 12.00 g (0.215 mol) of iron powder are added. The reaction mixture is stirred for 1.5 hours at 95 ° C, then suctioned over diatomaceous earth and washed with glacial acetic acid. The filtrate is diluted with water. The resulting precipitate is filtered off with suction, washed with water and dried. The product is purified by chromatography. Yield: 6.07 g (64%), HPLC-MS: method A, RT = 2.54 min, MH + = 399. The following compounds are analogously prepared: EXAMPLE 3: N-1- (4-amino-3-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolo G3 ', 4': 3,41-benzo-1, 2 -dl thiazole-7-ill-acetamide 3.92 g (9.1 mmol) of N- [1- (3-chloro-4-nitro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolo [ 3 ', 4': 3,4] benzo [1,2-d] thiazol-7-yl] -acetamide and 4.50 g (80.5 mmol) of iron powder. Yield: 3.6 g (100%), HPLC-MS: method A, RT = 3.99 min, MH + = 399. Example 4: N- [1- (2-chloro-4-methylamino-phenyl) -3-cyclopropyl-4 , 5-dihydro-1 H-pyrazolof3'.4 ': 3.41benzo-n, 2-dlthiazole-7-ill-acetamide 600 mg (1.50 mmol) of N- [1- (4-amino-2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolo [3 ', 4,: 3,4] benzo [1,2-d] thiazol-7-yl] -acetamide, 50 mg (1.67 mmol) of para-formaldehyde, 700 mg (3 mmol) of sodium acetoxyborohydride and 130 mg (2 mmol) of sodium acetate are stirred in 10 mL of tetrahydrofuran for 72 h at 60 ° C. Since a full reaction has not yet manifested, 5 mg of para-formaldehyde, 200 mg of sodium acetoxyborohydride and 40 mg of sodium acetate are again added and stirred for 16 h at 60 ° C. It is then mixed with dilute sodium hydrogen carbonate solution and the phases are separated. The organic phase is washed with water, dried and concentrated by evaporation to dryness. The residue is purified by chromatography Yield: 160 mg (26%), HPLC-MS: method A, RT = 2.73 min, MH + = 414/16. Example 5: 4- (f4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo-3'.4 ') tert-butyl ester: 3,41-benzo-1,2-d-thiazole-1-butyl ester ) -3-chloro-phenylaminol-metill-pipe dina-1-carboxylic acid 500 mg (1.25 mmol) of N- [1- (4-amino-2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1, 2-d] thiazol-7-yl] -acetamide, 319.90 mg (1.50 mmol) of 1-Boc-4-piperidinecarboxaldehyde, 380.50 mg (1.75 mmol) of sodium triacetoxyborohydride and 71.50 μ? _ (1.25 mmol) of glacial acetic acid are placed in 8 mL of dichloroethane and stirred under a nitrogen atmosphere for 16 h at room temperature. Then, the reaction mixture is combined with 5% potassium carbonate solution and the organic phase is separated. The aqueous phase is extracted with dichloromethane. The combined organic phases are dried and concentrated by evaporation to dryness. The residue is purified by chromatography, combined with suitable fractions, concentrated by evaporation to dryness and precipitated from ethyl acetate / petroleum ether. Yield: 281.6 mg (38%).

The following compounds are prepared analogously: Example 6: 4- (f4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo-3 ', 4': 3,41-benzo [1,2- dl t-azo-1-yl) -3-chloro-phenylamino-methyl.} - cyclohexane 150 mg (0.375 mmol) of N- [1- (4-amino-2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolo [3 ', 4': 3.4 is used. ] benzo [1,2-d] thiazol-7-yl] -acetamide, 50 μl (0.42 mmol) of cyclohexylcarboxaldehyde and 117 mg (0.525 mmol) of sodium triacetoxyborohydride. Yield: 93.3 mg (50%). HPLC-MS: method C, RT = 3.20 min, MH + = 565. Example 7: N- (1 - (2-chloro-4 - [(piperidin-4-ylmethyl) -amino-1-phenyl) -3-cyclopropyl hydrochloride -4,5-dihydro-1 H-pyrazolor3 ', 4': 3,41-benzoyl-1,2-dithiazole-7-yl) -acetamide 281 mg (0.471 mmol) of 4- tert.-butyl ester. { [4- (7- acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1, 2-d] thiazol-1-yl) -3-chloro-phenylamino] -methyl} -piperidine-1-carboxylic acid and 72.50 pL (0.941 mmol) of trifluoroacetic acid are placed in 20 mL of dichloromethane, and then stirred for 16 h at room temperature. After the addition of a little phosphate buffer, the solution is concentrated by evaporation in a vacuum. The residue is mixed with water and basified. The water phase is saturated with sodium chloride and extracted with tetrahydrofuran. The combined organic phases are dried and concentrated by evaporation to dryness. Precipitate the hydrochloride. Yield: 236 mg (94%). HPLC-MS: method C, RT = 3.18 min, MH + = 497. Example 8: N- (1 -. {2-Chloro-4 - [(1-cyclopentyl-piperidin-4-ylmethyl) -aminol- trifluoroacetate phenyl) -3-cyclopropyl-4,5-dihydro-1 Hp -razolor3 ', 4': 3,41benzon, 2-dlthiazol-7-yl) -acetamide 128 mg (0.240 mmol) of N- (1-. {2-chloro-4 - [(piperidin-4-ylmethyl) -amino] -phenyl] -3-cyclopropyl-4,5-dihydrohydrochloride 1 H-pyrazolo [3,, 4 ': 3,4] benzo [1,2-d] thiazol-7-yl) -acetamide, 25.49 pL (0.288 mmol) of cyclopentanone, 74.93 mg (0.336 mmol) of triacetoxyborohydride of sodium and 13.72 pL (0.240 mmol) of glacial acetic acid are stirred in 6 mL of dichloroethane for 48 hours at room temperature. The reaction mixture is combined with the % potassium carbonate and the phases are separated. The aqueous phase is extracted with dichloromethane and the combined organic phases are dried and concentrated by evaporation to dryness. The residue is dissolved in acetonitrile, water and trifluoroacetic acid and purified by chromatography. Yield: 40.10 mg (25%).

HPLC-MS: method C, RT = 3.39 min, MH + = 565. The following compounds are analogously prepared: Example 9: N- (1- (2-chloro-4-f (1-methyl-piperidin-) trifluoroacetate 4-ylmethyl) -amino-1-phenyl) -3-cyclo-propyl-4,5-dihydro-1 H-pyrazolo G3 ', 4': 3,41-benzo [1,2-dl thiazol-7-yl] -acetamide 150 mg (0.240 mmol) of N- (1-. {2-chloro-4 - [(piperidin-4-ylmethyl) -amino] -phenyl] -3-cyclopropyl-4,5- hydrochloride are used. dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-7-yl) -acetamide, 47.5 pL (0.6 mmol) of formaldehyde (37%) and 141.4 mg (0.64 mmol) of sodium triacetoxyborohydride. Yield: 204 mg (92%). HPLC-MS: method C, RT = 3.22 min, MH + = 511. Example 10: N- (1- {2-chloro-4-r (1-propyl-piperidin-4-ylmethyl) -amino1- trifluoroacetate phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolor3 ', 4': 3,41benzof1, 2-dlthiazol-7-yl) -acetamide 150 mg (0.240 mmol) of N- (1-. {2-chloro-4 - [(piperidin-4-ylmethyl) -amino] -phenyl] -3-cyclopropyl-4,5- hydrochloride are used. dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-7-yl) -acetamide, 26 pL (0.36 mmol) of propionaldehyde and 134.7 mg (0.6 mmol) of sodium triacetoxyborohydride. Yield: 103 mg (44%). HPLC-MS: method C, RT = 3.32 min, MH + = 539. Example 11: [4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolor3 ', 4': 3,41benzo [1, 2] 1-cyclopentyl-piperidine-4-carboxylic acid-dithiazole-1-iQ-3-chloro-phenyl-amide 100 mg (0.250 mmol) of N- [1- (4-amino-2-chloro-phenyl) -3-cyclopropyl-4,5-dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-7-yl] -acetamide, 96 pl (0.300 mmol) of TBTU and 100 pL (0.721 mmol) of triethylamine are placed in 5 mL of dichloromethane and stirred for 0.5 h at room temperature. They are added 70. 10 mg (0.278 mmol) of 1-cyclopentyl-p-pperidyl-4-carbonyl chloride and then stirred for 16 hours at room temperature. Then, the reaction mixture is diluted with dichloromethane and extracted with stirring with 5% potassium carbonate solution. The phases are separated through a phase separation cartridge and the aqueous phase is still extracted with dichloromethane. The combined organic phases are dried and concentrated by evaporation to dryness. The residue is purified by chromatography. The corresponding fractions are combined and concentrated by evaporation. The product is crystallized from ethyl acetate / petroleum ether and then purified once more by chromatography (HPLC) and lyophilized. Yield: 48.20 mg (28%), HPLC-MS: method A, RT = 2.53 min, MH + = 579. Example 12: f4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,41 benzo M, 2-d1 thiazolyl-3-chloro-phenyl-methyl-1-propyl-piperidine-4-carboxylic acid] 50 mg (0.121 mmol) of N- [1- (2-chloro-4-methylamino-phenyl) -3-cyclopropyl-4,5-dihydro-1 H -pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-7-yl] -acetamide and 60 mg (0.265 mmol) of 1-propyl-piperidin-4-carbonyl chloride are stirred in 1.50 mL of pyridine for 16 h at room temperature. Next, the mixture The reaction mixture is extracted with dichloromethane and dilute potassium carbonate solution. The organic phase is concentrated by evaporation with Extrelut and then purified by chromatography. The corresponding fractions are combined and concentrated by evaporation. The residue is crystallized with ethyl acetate / n-heptane. Yield: 25 mg (36%), HPLC-MS: method A, RT = 2.51 min, MH + 567/69. The following compounds are prepared analogously: Table B Ex. R2 R6 R5 Method RT [M + H] + B [min] 1 A 2.50 579 N ¾ OR 2 A 2.43 553/55 H3C Example 13: 4- (7-Acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo Í3 ', 4': 3,41 benzo f1, 2-d1 thiazol-1-yl) -3-chloro-N-methyl -N- (cis-4-pyrrolidin-1-yl-cyclohexyl) -benzamide 80 mg (0.187 mmol) of 4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-1-yl acid] ) -3-chloro-benzoic acid are placed in 5 ml_ of dichloromethane and 70 mg (0.218 mmol) of O- (1 H-benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium tetrafluoroborate are added. and 0.15 ml_ (1.08 mmol) of triethylamine. Stir for 15 min at room temperature and then add 50 mg (0.196 mmol) of methyl- (cis-4-pyrrolidin-1-yl-cyclohexyl) -amine. The The reaction mixture is stirred for 16 h at room temperature, then diluted with dichloromethane and extracted with 5% potassium carbonate solution. The organic phase is separated through a phase separation cartridge and concentrated by evaporation to dryness. The residue is crystallized from ethyl acetate. Yield: 70 mg (63%), HPLC-MS: method A, RT = 2.49 min, MH + 593/5. The following compounds are prepared analogously: Table C Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 1 H C 3.23 553 - to 2 H C 3.5 553 Xr-a NH2 Ex. R2 R6 R16 NR8R9 (= R24) Methods RT? +? C 0 [min] 3? C 3.18 519 * r-a 4 ? C 3.17 525 ? C 3.18 533 6? C 3.46 428 ??2 ? C 3.26 579 91 6 Ex. R2 R6 R1 NR8R9 (= R24) Methods RT M + H C 0 [min] 53 H C 3.21 511 a? 54 H A 2.47 537 55 H A 2.47 537 a 56 H C 3.16 511 a? Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 66 H A 2.56 607 to 67 H C 3.43 579 to-?" 68 H C 3.36 573 69 H C 3.42 593 70 H C 3.24 595 R16 Ex. R2 R6 NR8R9 (= R24) Method RT M + H C 0 [min] 71 H C 3.17 575 72 H C 3.23 533 ^ 6 73 H C 3.46 587 74 H C 3.39 573 Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 75 H C 3.32 545 76 H C 3.35 559 77 H C 3.18 575 78 H C 3.43 593 79 H C 3.21 595 R16 Ex. R2 R6 NR8R9 (= R24) Method RT M + H C or [min] 80 H to 2.55 573 81 H C 3.38 593 82 H C 3.43 593 83 H C 3.27 553 V-a Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C or [min] 89 H A 2.42 532 90 H C 3.19 575 91 H A 2.48 558 Xe- "92 H A 2.4 558 R16 Ex. R2 R6 NR8R9 (= R24) Method RT M + H C 0 [min] 93 H C 3.32 545 94 H C 3.24 573 95 H C 3.32 559 96 H A 2.60 565 97 H A 2.58 579 Xr-ci Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 98 H A 2.57 593 99 H A 2.54 593 100 H to 2.49 572 101 H A 2.48 572 Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 102 H A 2.55 607 103 H A 2.57 607 a-x 104 H A 2.49 586 105 H A 2.48 586 106 H C 3.4 579 xr-a R16 Ex. R2 R6 NR8R9 (= R24) Method RT M + H C 0 [min] 111 H A 2.56 607 112 H C 3.41 607 a-x 113 H C 3.35 593 114 H C 3.32 587 115 H C 3.32 587 R6 R16 Ej- R2 NR8R9 (= R24) Methods RT M + H C 0 [min] 116 H C 3.3 573 117 H C 3.52 621 a -v 118 H C 3.46 601 119 H C 3.46 601 Ex- R2 R6 R16 NR8R9 (= R24) Methods RT M + H C or [min] 125 H C 3.31 573 126 H A 2.54 576 127 H A 2.7 604 128 H A 2.53 576 Ex- R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 134 H A 2.48 536 135 H A 2.48 563 136 H A 2.53 590 Xé-F 137 H A 2.55 590 R 16 Ex- R2 6 R NR8R9 (= R24) Methods RT M + H C 0 [min] 152 H A 2.76 593 153 H A 2.72 591 154 H A 2.55 576 F 155 H A 2.55 591 Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C o [min] 156 H A 2.69 604 157 H A 2.62 576 F-,. 158 H A 2.75 618 F ~~ X16 159 H A 2.62 562 F ' 160 H A 2.55 562 120 R16 Ex. R2 R6 NR8R9 (= R24) Method RT M + H C 0 [min] 174 H A 2.59 590 175 H A 2.68 593 \ - / 176 H A 2.61 576 \ - 177 H A 2.49 537 178 H A 2.38 539 NH a Ex- R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 179 H A 2.38 518 NH \ 180 H A 2.48 518 NH 181 H A 2.48 522 X ÑH F 82 H A 2.45 522 NH Ex. R2 R6 R16 NR8R9 (= R24) Methods RT M + H C 0 [min] 192 H A 2.47 539 NH Xr-ci / 193 H X *. A 2.51 567 NH 194 H A 2.48 567 NH --- / \ 195 H A 2.65 607 NH 196 H A 2.45 609 NH x ^ -a Example 14: 2-f4- (7-acetylamino-3-cyclopropyl-4,5-d, 4-pyrazoloyl-3 ', 4': 3,41-benzofl, 2-dlthiazol-1-yl) -3-chloro-phenyl -acetamide 50 mg (0.1 13 mmol) of [4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazole-1] acid -yl) -3-chloro-phenyl] -acetic, 55.80 mg (0.147 mmol) of HATU and 95.45 μ? (0.700 mmol) of triethylamine are stirred in 4 mL of dichloromethane for 0.5 h at room temperature and then 225.78 μ? (0.452 mmol) of 2 molar ammonia solution in ethanol. The retraction mixture is stirred for 16 hours at room temperature. It is then extracted with 5% potassium carbonate solution and dichloromethane and the orgaphase is dried and concentrated by evaporation to dryness. The residue is purified by chromatography. The product is crystallized with ethyl acetate / petroleum ether. Yield: 16.60 mg (33%), HPLC-MS: method A, RT = 2.57 min, MH + = 441. Analogously the following compounds are prepared: Example 15: N-1 - (2-Chloro-4-hydroxy-phenyl) -3-cyclopropyl-4,5-dihydro-1 H-pyrazolo [3 ', 4': 3,41-benzori, 2-d-thiazole-7- il1-acetamida 192 mg (0.448 mmol) of 4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazol-1-yl acid] ) -3-chloro-phenyl-boronic and 38.51 μ? _ (0.448 mmol) of hydrogen peroxide (at 35%) are stirred in 4 mL of water for 16 hours at room temperature. The crude product is then filtered off with suction, washed with water and dried. Yield: 134.7 mg (75%). HPLC-MS: method C, RT = 3.58 min, MH + = 401. Example 16: trans-4- (7-acetylamino-3-cyclopropyl) -amide (1-cyclopentyl-piperidin-4-yl) -amide 4,5-dihydro-p -razolor3'.4 ': 3,41-benzo [1,2-d1-tiazol-1-n-cyclohexanecarboxylic acid 50 mg (0.125 mmol) of trans-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 \ 4 ': 3,4] benzo [1,2-d] thiazole-1-acid] il) -cyclohexanecarboxylic acid are placed in 3 mL of dimethylformamide and 60 mg (0.158 mmol) of HATU and 100 pL (0.588 mmol) of diisopropylethylamine are added. The reaction mixture is stir for 0.25 h at room temperature and then add 35 mg (0.145 mmol) of 4-amino-1-cyclopentyl-piperidine dihydrochloride. It is stirred for 1 hour at room temperature. The suspension is filtered with suction and the precipitate is washed with dimethylformamide and water and dried. Yield: 56 mg (81%). HPLC-MS: method A, RT = 2.40 min, MH + = 551. Example 17: cis-4- (7-acetylamino-3-cyclopropyl) 1- (cyclopentyl-piperidin-4-yl) -amide -4,5-dihydro-pyrazolof3 ', 4': 3,41-benzo [1,2-d1-thiazol-1-yl) -cyclohexanecarboxylic acid 50 mg (0.125 mmol) of cis-4- (7-acetylamino-3-cyclopropyl-4,5-dihydro-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] thiazole-1 acid) -yl) -cyclohexanecarboxylic acid are placed in 3 mL of dimethylformamide and 60 mg (0.158 mmol) of O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU) is added. and 100 μ? (0.588 mmol) of diisopropylethylamine. The reaction mixture is stirred for 0.25 hours at room temperature and then 35 mg (0.145 mmol) of 4-amino-1-cyclopentyl-piperidine dihydrochloride is added. It is stirred for 16 hours at room temperature. The solution is extracted with dichloromethane and 5% potassium carbonate solution. The organic phase is separated through a phase separation cartridge and concentrated by evaporation to dryness. The residue is purified by chromatography (semi-preparative RP-HPLC). The corresponding fractions are combined and lyophilized. 74 mg (89%). NMR: LG102885. HPLC-MS: method A, RT = 2.32 min, MH + = 551. In an analogous manner, the following compounds are prepared: Table E Stereo example R2 NR8R9 (= R24) Method RT [min] M + H E 1 cis A 2.26 551 2 cis A 2.40 565 Ej-stereo R2 NR8R9 (= R24) Method RT [min] M + H E 7 cis A 2.36 414 • N ^ CH3 8 cis A 2.28 400 ^ 4. NH2 9 trans A 2.41 565 trans A 2.35 551 Ej-stereo R2 NR8R9 (= R24) Method RT [min] M + H E 11 trans A 2.35 551 12 trans A 2.40 551 13 trans A 2.48 565 XXJ 14 trans A 2.34 525 CH3 Stereo example R2 NR8R9 (= R24) Method RT [min] M + H E 15 trans A 2.96 482 16 trans A 2.41 414 N ^ CH3 17 trans A 2.35 400 ^ 4, NH2 Example 18: N- (3-cyclopropyl-1 - [1 - (1-propyl-p -peridine-4-carbonyl) -p-peridn-4-n-4,5-dihydro-1Hp Razolof3 ', 4': 3,41-benzo [1,2-dl-thiazol-7-yl] -acetamide 100 mg (0.213 mmol) of N-. { 3-cyclopropyl-1- [1- (piperidine-4-carbonyl) - mg (0.344 mmol) of propionaldehyde and 37 mg (0.451 mmol) of sodium acetate are stirred in 10 mL of dichloromethane / acetonitrile for 24 hours at room temperature. It is then concentrated by evaporation and the residue is stirred with 10 mL of 5% potassium carbonate solution, filtered with suction and washed with water. The precipitate is purified by chromatography (HPLC). Yield: 43 mg (39%). HPLC-MS: method A, RT = 2.34 min, MH + = 511/569. The following compounds are prepared analogously: Table F Example 19: N- (3-cyclopropyl-1 - [1- (4-isopropyl-piperazine-1 -carbonyl) -pyridin-4-yl-1-4.5-dihydro-1H-pyrazoloyl3 ', 4': 3 , 41-benzo [1,2-dithiazol-7-yl] -acetamide 100 mg (0.254 mmol) of N- (3-cyclopropyl-1-piperidin-4-yl-4,5-dihydro-1 H-pyrazolo [3 ', 4': 3,4] benzo [1,2-d] ] tiazol-7-yl) -acetamide, 25 mg (0.084 mmol) of triphosgene and 78 μl (0.563 mmol) of triethylamine are placed in 20 mL of dichloromethane / tetrahydrofuran and stirred for 1 hour at reflux . It is then mixed with 33 mg (0.257 mmol) of isopropyl-piperazine and stirred for 24 hours at room temperature. It is then concentrated by evaporation and the residue is mixed with 10 ml of potassium hydrogen carbonate solution and filtered with suction. The precipitate is purified by chromatography (HPLC). Yield: 20 mg (15%). HPLC-MS: method A, RT 512. Analogously to the following compounds are prepared: BIOLOGICAL ASSAY The compounds of the formula (I) mentioned by way of example are distinguished by an affinity to PI3-kinase, that is to say in the assay for an IC5 value below 600 nmol / liter. In order to be able to determine the inhibitory activity of the compounds on the ?? 3 ?? an in-vitro kinase assay was employed. The expression and purification of Tß ^ - ?? e and p101-GST / p1 10y from Sf9 cells (Spodoptera frugiperda 9) has already been described previously (Maier et al., J. Biol. Chem. 1999 (274) 29311- 29317). Alternatively, the following procedure was used for the determination of the activity: 10 pl of the compound to be tested were placed in 96-well PVDF filter plates (0.45 μ?) And incubated for 20 min with 30 μ? of lipid vesicles (PIP2 (0.7 μg / well) I phosphatidylethanolamine (7.5 pg / well), phosphatidylserine (7.5 pg / well), sphingomyelin (0.7 pg / well) and phosphatidylcholine (3.2 pg / well)), containing 1- 3 ng of ?? 3 ?? and 20-60 ng of G iy2-His. By adding 10 μ? of buffer of reaction (40 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM EGTA, 1 mM β-glycerophosphates, 1 mM DTT, 7 mM MgCl 2 and 0.1% BSA, 1 μ? of ATP and 0.2 pCi [? -33? ] -ATP) the reaction was started and incubated for 120 min at room temperature. The reaction solution was filtered through the filters by applying a vacuum and washing continued with 200 μ? of PBS. After drying the plates at 50 ° C, the radioactivity remaining on the plates was determined after the addition of 50 μ? of scintillation fluid with the help of a Top-Count measuring device. SECTORS OF INDICATION As it was found, the compounds of the formula (I) are distinguished by multiple possibilities of application in the therapeutic sector. The possibilities of application for which the compounds of the formula (I) according to the invention can be used preferably by virtue of their pharmaceutical activity as modulators of PI3-kinase should be emphasized. Expressed in a general way, these are diseases whose pathology involves an activity of PI3-kinases, in particular inflammatory and allergic diseases. In particular, inflammatory and allergic diseases of the respiratory tract, inflammatory diseases of the gastrointestinal tract, inflammatory diseases of the motor apparatus, inflammatory and allergic diseases of the skin, inflammatory diseases of the eyes, diseases of the nasal mucosa, inflammatory pathological conditions or allergic reactions involving autoimmune reactions, or inflammation of the kidneys. The treatment can be carried out in this case in a symptomatic, adaptive, curative or preventive way.

Respiratory diseases preferably mentioned would be in this case chronic and / or obstructive respiratory diseases. The compounds of the formula (I) according to the invention can determine in this case, by virtue of their pharmacological properties, a reduction of the tissue destruction of the inflammation of the respiratory tracts of the bronchial hyperreactivity of the process. of reconstitution of the lungs as a consequence of the inflammation • of the worsening of the disease (progression). Particularly preferred are the compounds according to the invention for the preparation of a medicament for the treatment of chronic bronchitis, acute bronchitis, bronchitis due to bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive pulmonary disease (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic rhinitis or not allergic, chronic sinusitis, cystic fibrosis or mucoviscidosis, lack of alpha-1-antitrypsin, cough, pulmonary emphysema, interstitial lung diseases such as, for example, pulmonary fibrosis, asbestosis and silicosis and alveolitis; hyperreactive airways, nasal polyps, pulmonary edema such as, for example, toxic pulmonary edema and ARDS / IRDS, pneumonitis by virtue of various genesis such as induced by irradiation or by aspiration, or infectious collagenoses, such as lupus erythematosus, systemic scleroderma, sarcoidosis or Boeck's disease.

Also suitable are the compounds of formula (I) for the treatment of skin diseases such as, for example, psoriasis, contact dermatitis, atopic dermatitis, Alopecia areata (circular hair loss), erythema exudative multiforme (Stevens syndrome). -Johnson), dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria), lupus erythematosus, follicular and superficial pyoderma, endogenous and exogenous acne, acne rosacea, as well as other inflammatory or allergic or proliferative skin diseases. In addition, the compounds of the formula (I) are suitable for therapeutic use in inflammatory or allergic conditions involving autoimmune reactions such as, for example, inflammatory bowel diseases, for example Crohn's disease or ulcerative colitis; circle diseases of arthritis such as, for example, rheumatoid or psoriatic arthritis, osteoarthritis, rheumatoid spondylitis and other arthritic conditions or multiple sclerosis. In addition, the following general inflammatory or allergic diseases, which can be treated by drugs containing compounds of the formula (I), must be mentioned: • inflammations in the eyes such as, for example, inflammation of the conjunctiva (conjunctivitis) of different types such as, for example, infections with fungi or bacteria, allergic conjunctivitis, irritant conjunctivitis, drug-induced conjunctivitis, keratitis, uveitis • diseases of the nasal mucosa such as, for example, rhinitis / allergic sinusitis or nasal polyps Inflammatory or allergic disease states such as, for example, systemic lupus erythematosus, chronic hepatitis, inflammations of the kidneys, such as glomerulonephritis, interstitial nephritis or nephrotic or idiopathic syndrome. As other diseases that can be treated, by virtue of the pharmacological activity of the compounds of the formula (I) containing them with a medicament, toxic or septic shock syndrome, atherosclerosis, inflammation of the middle ear (otitis) can be mentioned. media), hypertrophy of the heart, heart failure, stroke, ischemia-reperfusion injury or neurodegenerative diseases such as Parkinson's or Alzheimer's disease. COMBINATIONS The compounds of the formula (I) can be used alone or in combination with other active ingredients of the formula (I). Optionally, the compounds of the formula (I) can also be used in combination with W, wherein W represents a pharmacologically active principle and, for example, is selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists. , EGFR inhibitors, dopamine agonists, H1 anti-histamines, PAF antagonists and PI3 kinase inhibitors, preferably PI3-6 kinase inhibitors. In addition, combinations of two or three times of W can be combined with the compounds of the formula (I). Combinations of W mentioned by way of example would be: W represents a betamimetic, combined with an active principle selected from the group consisting of anticholinergics, corticosteroids, PDE4 inhibitors, EGFR inhibitors and LTD4 antagonists, W represents an anticholinergic, combined with an active ingredient selected from the group consisting of betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors and LTD4 antagonists, - W represents a corticosteroid, combined with an active principle selected from the group consisting of PDE4 inhibitors, EGFR inhibitors and LTD4-W antagonists represents a PDE4 inhibitor, combined with a Active ingredient selected from the group consisting of EGFR inhibitors and LTD4-W antagonists represents an EGFR inhibitor, combined with an LTD4 antagonist. As betamimetics, compounds which are chosen from the group consisting of albuterol are preferably used in this case, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetarin, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol , sulfonterol, terbutaline, thiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and 3- (4-. {6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl)] ) -ethylamino] -hexyloxy.} - butyl) -benzylsulfonamide 5- [2- (5,6-diethyl-indan-2-ylamino) -1-hydroxy-ethyl] -8-hydroxy-1 H-quinoline -2-one 4- hydroxy-7- [2-. { [2-. { [3- (2-phenylethoxy) propyl] sulfonyl} ethyl] -amino} ethyl] -2 (3H) -benzothiazolone 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol 1- [3- (4-methoxybenzyl) -amino) -4-hydroxyphenyl] -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol 1 - [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin- 8-yl] -2- [3- (4-N, N-dimethylaminophenyl) -2-methyl-2-propylamino] ethanol 1 - . 1 - [2 H -5-hydroxy-3-oxo-4 H -1,4-benzoxazin-8-yl] -2- [3- (4-methoxyphenyl) -2-methyl-2-propylamino] ethanol 1 - [2H -5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-n-butyloxyphenyl) -2-methyl-2-propylamino] ethanol 1 - [2H-5 -hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2-. { 4- [3- (4-methoxyphenyl) -1, 2,4-triazol-3-yl] -2-methyl-2-butylamino} 5- Hydroxy-8- (1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazin-3- (4H) -one 1- (4-amino-3-chloro-5-trifluoromethylphenyl) -2- ethanol tert.-butylamino) ethanol 6- hydroxy-8-. { 1-hydroxy-2- [2- (4-methoxy-phenyl) -1,1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one 6-hydroxy-8-. { 1-Hydroxy-2- [2- (4-phenoxy-acetic acid ethyl ester) -1, 1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one 6-hydroxy-8-. { 1-hydroxy-2- [2 - (4-phenoxy-acetic acid) -1, 1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one 8-. { 2- [1,1-dimethyl-2- (2,4,6-trimethylphenyl) -ethylamino] -1-hydroxy-ethyl} -6-hydroxy benzo [1,4] oxazin-3-one 6-hydroxy-8-. { 1-hydroxy-2- [2- (4-hydroxy-phenyl) -1,1-dimethyl-ethylamino] -eti-benzo [1,4] oxazin-3-one 6-hydroxy-8-. { 1-hydroxy-2- [2- (4-isopropyl-phenyl) -1,1-dimethyl-ethylamino] -ethyl} -4H benzo [1,4] oxazin-3-one 8-. { 2- [2- (4-ethyl-phenyl) -1, 1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3-one 8-. { 2- [2- (4-ethoxy-phenyl) -1, 1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3-one 4- (4-. {2- [2-Hydroxy-2- (6-hydroxy-3-oxo-3,4-dihydro-2H-benzo [1,4] oxazin-8-yl) -ethylamino] -2-methyl-propyl.}. -phenoxy) -butyric 8-. { 2- [2- (3,4-difluoro-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy benzo [1,4] oxazin-3-one 1- (4-ethoxy-carbonylamino-3-cyano-5-fluorophenyl) -2- (tert-butylamino) ethanol, optionally in the form of their racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophophate, hydromethane sulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. Anticholinergics are preferably used in this case as compounds selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine. In the salts mentioned above, the cations represent the pharmacologically active components. The salts mentioned above may contain as anions preferably chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate, being preferred as conjugated ions chloride, bromide, iodide, sulfate, methanesulfonate or p- toluenesulfonate. Of all the salts, chlorides, bromides, iodide and methanesulfonate are particularly preferred. Other compounds that are named are: tropenolic ester metobromide of 2,2-diphenylpropionic acid methobromide of 2,2-diphenylpropionic acid scopin ester metochromide of 2-fluoro-2,2-diphenylacetic acid methobromide, tropenolic acid ester methobromide 2-Fluoro-2,2-diphenylacetic acid 1,3,3,4,4-tetrafluorobenzyl tropenic acid methobromide 3,3 ', 4,4'-tetrafluorobenzyl methopenic ester metobromide 1,3-tropenic acid methobromide , 4'-difluorobenzyl 4,4'-difluorobenzyl scopin ester ester metobromide 3,3-difluorobenzyl tropenic acid methobromide 1,3'-difluorobenzyl polyphenolic ester metobromide tropenolic ester-9-hydroxy acid methobromide -fluoren-9-carboxylic acid tropenolic ester methobromide 9-fluoro-fluoren-9-carboxylic acid ester metochromide 9-hydroxy-fluoren-9-carboxylic acid methobromide 9-fluoro-fluoren-9-carboxylic acid scopic ester, tropenol ester ester of 9-methyl-fluoren-9-carboxylic acid, 9-methyl-fluoren-9-carboxylic acid scopin ester ester, cyclopropyl-proproline ester, methobromide benzyl cyclopropyl-thrombinic acid ester methobromide 2, 2-diphenylpropionic acid cyclopropylpropionic ester ester of 9-hydroxy-xanthen-9-carboxylic acid cyclopropylpropionic ester ester of 9-methyl-fluoren-9-carboxylic acid 9-Methyl-xanten-9-carboxylic acid cyclopropyl-proproline ester metobromide cyclopropyl-proproline ester of 9-hydroxy-fluoren-9-carboxylic acid methyl ester-cyclopropyl-thrucropic ester 4,4'-difluorobenzyl ester 9-hydroxy-xanten-9-carboxylic acid 9-hydroxy-xanten-9-carboxylic acid scopin ester methobromide 9-methyl-xanthen-9-carboxylic acid tropenolic ester methochromide 9-methyl-methyl-scopin ester xanten-9-carboxylic acid tropenolic ester methobromide 9-ethyl-xanthen-9-carboxylic acid methobromide tropenolic ester of 9-difluoromethyl-xanten-9-carboxylic acid methobromide of 9-hydroxymethyl-xanten-9-carboxylic acid scopin ester Corticosteroids are preferably used in this case to be compounds selected from the group consisting of prednisolone, prednisone, butyclocortipropionate, flunisolide, clometasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, betamethasone, Deflazacort, RPR-106541, NS-126, ST-26 and - ester (S) -6,9-difluoro-17- [Fluoromethyl] - [ (2-furanylcarbonyl) oxy] -11-hydroxy-16-methyl-3-oxo-androsta-1,4-dien-17-carbothionic ester (S) - (2-oxo-tetrahydro-furan-3S-ylco) 6,6-difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-dien-17-carbothionic acid dichloroacetate acid, optionally in the form of their racemates, enantiomers or diastereoisomers, and optionally in the form of their salts and derivatives, of their solvates and / or hydrates. Any reference to steroids includes a reference to their salts or possibly existing derivatives, hydrates or solvates. Examples of possible salts and derivatives of the steroids may be: alkali metal salts such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates, or else furoates. Preferred PDE4 inhibitors are preferably compounds selected from the group consisting of enprophyllin, theophylline, Roflumilast, Ariflo (Cilomilast), Tofimilast, Pumafentrin, Lirimilast, Arofilin, Atizoram, D-4418, Bay-198004, BY343. , CP-325,366, D-4396 (Sch-351591), AWD-2-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V -11294A, CI-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and N- (3,5-dichloro-1-oxo-pyridin-4-yl) -4-difluoromethoxy -3-cyclopropylmethoxybenzamide (-) p - [(4aR *, 10¿ »S *) - 9-ethoxy-1, 2,3,4,4a, 10b-hexahydro-8-methoxy-2-methylbenzo [s] [ 1, 6] naphthyridin-6-yl] -N, N-diisopropylbenzamide (R) - (+) - 1- (4-bromobenzyl) -4 - [(3-cyclopentyloxy) -4-methoxyphenyl] -2-pyrrolidone 3 - (cyclopentyloxy-4-methoxyphenyl) -1 - (4-N '- [N-2-cyano-S-methyl-isothioureido] benzyl) -2-pyrrolidone cis-acid 4-cyano-4- (3-cyclopentyloxy-4-) methoxyphenyl) cyclohexane-1-carboxylic acid] 2-carbomethoxy-4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexan-1-one cis [4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexan-1-ol] [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate of (R) - (+) -ethyl (4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate (S) - (-) - ethyl 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (2- thienyl) -9 / - / - pyrazolo [3,4-c] -1, 2,4-triazolo [4,3-a] pyridine 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (tert. .-butyl) -9H-pyrazolo [3,4-c] -1, 2,4-triazolo [4,3-a] pyridine, optionally in the form of their racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophophate, hydromethane sulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. As LTD4 antagonists, they are used in this case, preferably compounds that are selected from the group consisting of montelukast, pranlukast, zafirlukast, CC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L- 733321 y - acid 1 - (((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) -phenyl) ) thio) methylcyclopropan-acetic acid, - 1 - (((1 (R) -3 (3- (2- (2,3-dichlorothieno [3,2-b] pyridin-5-yl) - (E) - ethenyl) phenyl) -3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropanacetic acid [2 - [[2- (4-tert-butyl-2-thiazolyl) - 5-benzofuranyl] oxymethyl] phenyl] acetic acid, optionally in the form of its racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophophate, hydromethane sulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. Salts or derivatives, for the formation of which are optionally suitable, the LTD 4 antagonists are understood, for example: alkali metal salts such as, for example, sodium or psium salts, alkaline earth metal salts, sulfobenzoates, phosphates, isonicotinates, acetates , propionates, dihydrogen phosphates, palmitates, pivalates, or else furoate. As EGFR inhibitors, they are used in this case, preferably compounds selected from the group consisting of Cetuximab, Trastuzumab, ABX-EGF, monoclonal antibody ICR-62 and -4 - [(3-chloro-4-fluorophenyl) amino] - 6- { [4- (morpholin-4-yl) -1 -oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-diethylamino) -1 -oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline-4 - [(R) - (1-phenyl-ethyl) amino] -6-. { [4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopentyloxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { [4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1 -oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { [4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-??? - 2-buten-1-yl] amino} -7 - [(S) - (tetrahydrofuran-3-yl) oxy] -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { [4 - ((R) -2-methoxymethyl-6-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline 5 - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) - ethoxy] -7-methoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6- (. {4- [N- (2-methoxy-ethyl) -N-methyl-amino] - 1-oxo-2-buten-1-yl.}. Amino) -7-cyclopropylmethoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-cyclopentyloxy-quinazoline-4 - [(R) - (1-phenyl-ethyl) amino] -6-. { [4- (N, N-bis- (2-methoxy-ethyl) -amino) -1-??? - 2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline-4 - [(R) - (1-phenyl-ethyl) amino] -6- (. {4- [N- (2-methoxy-ethyl) -N-ethyl-amino] - 1-??? - 2-buten-1-yl.}. Amino) -7-cyclopropylmethoxy-quinazoline 5. 4 - [(R) - (1-phenyl-ethyl) amino] -6- (. {4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1 - ??? - 2 -buten-1-yl.}. amino) -7-cyclopropylmethoxy-quinazoline-4 - [(R) - (1-phenyl-ethyl) amino] -6- (. {4- [N- (tetrahydropyran-4 -yl) -N-methyl-amino] -1 -oxo-2-buten-1-yl.}. amino) -7-cyclopropylmethoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6 -. { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7 - ((R) -tetrahydrofuran-3-yloxy) -quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-dimethylamino) -1 -oxo-2-buten-1-yl] amino} -7 - ((S) -tetrahydrofuran-3-yloxy) -quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6- (. {4- [N- (2-methoxy-ethyl)] -N-methyl-amino] -1 -oxo-2-buten-1-yl.}. Amino) -7-cyclopentyloxy-quinazoline - 4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N-cyclopropyl-N-methyl-amino) -1 -oxo-2-buten-1-yl} Not me} -7-cyclopentyloxy-quinazolin-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7 - [(R) - (tetrahydrofuran-2-yl) methoxy] -chinazoln-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7 - [(S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline-4 - [(3-ethynyl-phenyl) amino] -6,7-bis- (2-methoxy-ethoxy) -quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -7- [3- (morpholin-4-yl) -propyloxy] -6 - [(vinylcarbonyl) amino] -quinazoline-4 - [(R) - (1 phenyl-ethyl) amino] -6- (4-hydroxy-phenyl) -7H-pyrrolo [2,3-d] pyrimidine-3-cyano-4 - [(3-chloro-4-fluorophenyl) amino] -6 -. { [4- (N, N-dimethylamino) -1 -oxo-2-buten-1-yl] amino} -7-ethoxy-quinoline - 4-. { [3-chloro-4- (3-fluoro-benzyloxy) -phenyl] amino} -6- (5- { [(2-Methanesulfonyl-ethyl) amino] methyl.}. -furan-2-yl) quinazoline-4 - [(R) - (1-phenyl-ethyl) amino] -6 -. { [4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6-. { [4- (morpholin-4-yl) -1 -oxo-2-buten-1-yl] amino} -7 - [(tetrahydrofuran-2-yl) methoxy] -quinazoline-4 - [(3-chloro-4-fluorophenyl) amino] -6- (. {4- [N, N-bis- (2-methoxy-ethyl) -N-methyl-amino] -1-oxo-2-buten-1-yl} amino) -7 - [(tetrahydrofuran-2-yl) methoxy] -quinazoline-4 - [(3-ethynyl-phenyl) amino] -6-. { [4- (5,5-dimethyl-2-oxo-morpholin-4-yl) -1 -oxo-2-buten-1-yl] amino} -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7-methoxy- quinazoline - 4 - [(3-chloro-4-fluoro-pheny] amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7 - [(R) - (Tetrahydrofuran-2-yl) methoxy] -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -7- [2- (2,2-dimethyl-6 -oxo-morpholin-4-yl) -ethoxy] -6 - [(S) - (tetrahydrofuran-2-yl) methoxy] -quinazol -na-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 2- [4- (2-Oxo-morpholin-4-yl) -piperidin-1-yl] -ethoxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (tert-butyloxycarbonyl) -piperidin-4-yloxy] -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-amino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro- phenyl) amino] -6- (trans-4-methanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-3) -iloxy) -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro- phenyl) amino] -6-. { 1 - [(Morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(methoxymethyl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (piperidin-3-yloxy) -7-methoxy-quinazoline - 4 - [(3-Chloro-4-fluoro-phenyl) amino] -6- [1- (2-acetylamino-ethyl) -piperidin-4-yloxy] -7-methoxy-quinazoline-4 - [(3- chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7-ethoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - ((S) -tetrahydrofuran-3-yloxy) -7-hydroxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline-4 - [(3-chloro-4- fluoro-phenyl) amino] -6-. { trans -4 - [(dimethylamino) sulfonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { trans -4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { trans-4 - [(morpholin-4i-l) sulfonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-acetylamino-ethoxy) -quinazoline-4 - [( 3-Chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methanesulfonylamino-ethoxy) -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] ] -6-. { 1 - [(piperidin-1-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-aminocait) onylmethyl-piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [( 3-Chloro-4-fluoro-phenyl) amino] -6- (cis-4- { N - [(tetrahydropyran-4-yl) carbonyl] -N-methyl-amino.} - cyclohexan-1-yloxy ) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- { N - [(morpholin-4-yl) carbonyl] -N- methyl-amino.}. -cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N- [ (morpholin-4-yl) sulfonyl] -N-methyl-amino.} - cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - (trans-4-ethanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-ethoxy-quinazoline-4 - [(3-chloro-4-fluoro- phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -qualanzo-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7- (2-methoxy-ethoxy) -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] - 6- (cis-4-acetylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-ethynyl-phenyl) amino] -6- [1- (tert-butyloxycarbonyl) -piperidin-4 -yloxy] -7-methoxy-quinazoline-4 - [(3-ethynyl-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro phenyl) amino] -6- (cis-4- { N - [(piperidin-1-yl) carbonyl] -N-methyl-amino.} - cyclohexan-1-yloxy) -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- { N - [(4-methyl-piperazin-1-yl) carbonyl] -N-methyl-amino .}. -cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { cis-4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [2- (2-Oxopyrrolidin-1-yl) ethyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 ^ (2-methoxy-ethoxy) -quinazoline-4 - [(3-ethynyl-phenyl) amino] -6- (1-acetyl-piperidin-4-yloxy) -7-methoxy-quinazoline - 4 - [(3-ethynyl-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline - 4 - [(3-ethynyl-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline - 4 - [(3-Chloro-4-fluoro-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline-4 - [(3- chloro-4-fluoro-phenyl) amino] -6- (1-isopropyloxycarbonyl-piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { cis-4- [N- (2-methoxy-acetyl) -N-methyl-amino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline-4 - [(3-ethynyl-phenyl) amino] -6- (piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [(3-ethynyl-phenyl) amino] -6 - [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7-methoxy-quinazoline-4 - [(3-ethynyl-phenyl) amino] -6-. { 1 - [(Morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(cis-2,6-dimethyl-morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(2-methyl-morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(S, S) - (2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(N-methyl-N-2-methoxyethyl-amino) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-ethyl-piperidin-4-yloxy) -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(2-methoxyethyl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline - 4 - [(3-chloro-4-fluoro-phenyl) amino] -6-. { 1 - [(3-methoxypropyl-amino) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [cis-4- [N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] - 7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [cis-4- [N-acetyl-N-methyl-amino) -cyclohexan-1-yloxy] -7 -methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro 4-fluoro-phenyl) amino] -6- [trans-4- [N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline-4 - [(3-chloro- 4-fluoro-phenyl) amino] -6- (trans-4-dimethylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4- { N - [(morpholin-4-yl) carbonyl] -N-methi amino.}. -cyclohexan-1-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro- 4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7 - [(S) - (tetrahydrofuran-2-yl) methoxy ] -quinazoline-4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline-4 - [(3-chloro-4 -fluoro-phenyl) amino] -6- (1-cyano-piperi din-4-yloxy) -7-methoxy-quinazoline, optionally in the form of their racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, are preferred. hydrometanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. As dopamine antagonists they are used in this case, preferably compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and violace, optionally in the form of their racemates. , enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophophate, hydromethane sulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate are preferred., hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. As H1 antihistamines, they are used in this case, preferably compounds that are chosen from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetinden, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine. , dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of their racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydrometanesulfonate, h id treatment, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. As PAF antagonists they are used in this case, preferably compounds which are selected from the group consisting of -4- (2-chlorophenyl) -9-methyl-2- [3- (4-morpholinyl) -3-propanon-1- il] -6H-thieno- [3,2-f] - [1, 2,4] triazolo [4,3-a] [1,4] diazepine-6- (2-chlorophenyl) -8,9-dihydro -1-methyl-8 - [(4-morpholinyl) carbonyl] -4H, 7H-cyclopenta- [4,5] thieno- [3,2-f] [1, 2,4] triazolo [4,3-a] ] [1,4] diazepine, optionally in the form of their racemates, enantiomers, diastereoisomers, and optionally in the form of their salts by the addition of pharmacologically compatible acids, solvates or hydrates. According to the invention, the acid addition salts of the betamimetics chosen from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophophate, hydromethane sulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotrearate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. As inhibitors of PI3-kinase-6 are used in this case, preferably compounds selected from the group consisting of: IC87114, 2- (6-aminopurin-9-ylmethyl) -3- (2-chlorophenyl) -6,7 -dimethoxy-3H-quinazolin-4-one; 2- (6-aminopurin-o-ylmethyl) -6-bromo-3- (2-chlorophenyl) -3H-quinazolin-4-one; 2- (6-aminopu-rin-o-ylmethyl) -3- (2-chlorophenyl) -7-fluoro-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -6-chloro-3- (2-chlorophenyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2-chlorophenyl) -5-fluoro-3H-quinazolin-4-one; 2- (6-aminopurin-o-ylmethyl) -5-chloro-3- (2-chloro-phenyl) -3H-quinazolin-4-one; 2- (6-Aminopurin-9-ylmethyl) -3- (2-chlorophenyl) -5-methyl-3H-quinazolin-4-one; 2- (6- aminopurin-9-ylmethyl) -8-chloro-3- (2-chlorophenyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3-biphenyl-2-yl-5-chloro-3H-quinazolin-4-one; 5-chloro-2- (9H-purin-6-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 5-chloro-3- (2-fluorophenyl) -2- (9H-purin-6-yl-sulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-chloro-3,5- (2-fluorophenyl) -3H-quinazolin-4-one; 3-biphenyl-2-yl-5-chloro-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 5-chloro-3- (2-methoxyphenyl) -2- (9H-purin-6-yl sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5-fluoro-2- (9H-purin-6-yl sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -6,7-dimethoxy-2- (9H-purin-6-yl sulfanylmethyl) -3H-quinazolin-4-one; 6-bromo-3- (2-chlorophenyl) -2- (9H-purin-6-yl- or sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -8-trifluoromethyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -2- (9H-purin-6-ylsulfanylmethyl) -3H-benzo [g] quinazolin-4-one; 6-chloro-3- (2-chlorophenyl) -2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 8-chloro-3- (2-chlorophenyl) -2- (9H-purin-6 sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -7-fluoro-2- (9H-purin-6-sulfanyl-methyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -7-nitro-2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -6-hydroxy-2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 5-chloro-3- (2-chlorophenyl) -2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5-methyl-2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -6,7-difluoro-2- (9H-purin-6-or sulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -6-fluoro-2- (9H-purin-6-sulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2-isopropylphenyl) -5-methyl-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 3- (2-fluorophenyl) -5-methyl-2- (9H-purin-6-yl-sulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-chloro-3-o-tolyl-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-chloro-3- (2-methoxy-phenyl) -3H-quinazolin-4-one; 2- (2- amino-9H-purin-6-ylsulfanylmethyl) -3-cyclopropyl-5-methyl-3H-quinazolin-4-one; 3- cyclopropylmethyl-5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (6- aminopurin-9-ylmethyl) -3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one; 2- (2-amino-9H-purin-6-ylsulfanylmethyl) -3-cyclopropylmethyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3,6-phenethyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (2-amino-9H-purin-6-ylsulfanylmethyl) -5-methyl-3-phenethyl-3H-quinazolin-4-one; 3-cyclopentyl-5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3-cyclopentyl-5-methyl-3H-quinazolin-4-one; 3- (2-chloropyridin-3-yl) -5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2-chloropyridin-10 3-yl) -5-methyl-3H-quinazoln-4-one; 3-methyl-4- [5-methyl-4-oxo-2- (9H-purin-6-ylsulfanylmethyl) -4H-quinazolin-3-yl] -benzoic acid; 3-cyclopropyl-5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3-cyclopropyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3- (4-nitrobenzyl) -2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3-cyclohexyl-5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-! _ 5-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3-cyclohexyl-5-methyl-3H-quinazolin-4-one; 2- (2-amino-9H-purin-6-ylsulfanylmethyl) -3-cyclohexyl-5-methyl-3H-quinazolin-4-one; 5-methyl-3- (E-2-phenylcyclopropyl) -2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5-fluoro-2 - [(9H-purin-6-ylamino) methyl] -3H-quinazolin-4-one; 2- [(2-amino-9H-purin-6-ylamino) methyl] -3- (2-chlorophenyl) -5-fluoro-3H-quinazolin-4-one; 2 or 5-methyl-2 - [(9H-purin-6-ylamino) methyl] -3-o-tolyl-3H-quinazolin-4-one; 2 - [(2-amino-9H-purin-6-ylamino) -methyl] -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2 - [(2-fluoro-9H-purin-6-ylamino) methyl] -5-methyl-3-o-tolyl-3H-quinazolin-4-one; (2-chlorophenyl) -dimethylamino- (9H-purin-6-ylsulfanyl-methyl) -3H-quinazolin-4-one; 5- (2-benzyloxyethoxy) -3- (2-chlorophenyl) -2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5-5-fluoro-4-oxo-3,4-dihydro-quinazol-n-2-ylmethyl ester of 6-aminopurine-9- carboxylic; N- [3- (2-chlorophenyl) -5-fluoro-4-oxo-3,4-dihydro-quinazolin-2-ylmethyl] -2- (9H-purin-6-ylsulfanyl) -acetamide; 2- [1- (2-Fluoro-9H-purin-6-ylamino) ethyl] -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- [1- (9H-purin-6-ylamino) ethyl] -3-o-tolyl-3H-quinazolin-4-one; 2- (6-dimethylaminopurin-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (2-methyl-6-oxo-1,6-dihydro-purin-7-ylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (2-methyl-6-oxo-1,6-dihydro-purin-9-ylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 2- (Amino-dimethylaminopurin-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (2-amino-9H-purin-6-ylsulfanylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (4-amino-1, 3,5-triazin-2-ylsulfanylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (7-methyl-7H-purin-6-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (2-oxo-1,2-dihydro-pyrimidin-4-ylsulfan-N-methyl) -3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-purin-7-ylmethyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2-purin-9-ylmethyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (9-methyl-9H-purin-6-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 2- (2,6-diamino-pyrimidin-4-ylsulfanylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (5-methyl- [1, 2,4] triazolo [1, 5-a] pyrimidin-7-sulfosylmethyl) -3-o-tolyl-3H-quinazolin-4- ona; 5-methyl-2- (2-methylsulfanyl-9H-purin-6-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 2- (2-hydroxy-9H-purin-6-ylsulfanylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (1-methyl-1 H-imidazol-2-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 5-methyl-3-o-tolyl-2- (H- [1, 2,4] triazol-3-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (2-amino-6-chloro-purin-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (6-aminopurin-7-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (7-amino-1, 2,3-triazolo [4,5-d] pyrimidin-3-yl-methyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (7-amino-1, 2,3-triazolo [4,5-d] pyrimidin-1-methyl-methyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (6-amino-9H-purin-2-ylsulfanylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (2-amino-6-ethylamino-pyrimidin-4-ylsulfanylmethyl) -5-methyl-3-o- tolyl-3H-quinazolin-4-one; 2- (3-amino-5-methylsulfanyl-1, 2,4-triazol-1-methyl-methyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (5-amino-3-methylsulfanyl-1, 2,4-triazol-1-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (6-methylaminopurin-9-ylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 2- (6-benzylamino-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (2,6-diaminopurin-9-ylmethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3-o-tolyl-3H-quinazolin-4-one; 3-isobutyl-5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; N-. { 2- [5-methyl-4-oxo-2- (9H-purin-6-ylsulfanylmethyl) -4H-quinazolin-3-yl] -phenyl} -acetamide; 5-methyl-3- (E-2-methyl-cyclohexyl) -2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- [5-methyl-4-oxo-2- (9H-purin-6-ylsulfanylmethyl) -4H-quinazolin-3-yl] -benzoic acid; 3-. { 2 - [(2-dimethylaminoethyl) methylamino] phenyl} -5-methyl-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5-methoxy-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3- (2-chlorophenyl) -5- (2-morpholin-4-yl-ethylamino) -2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 3-benzyl-5-methoxy-2- (9H-purin-6-ylsulfanylmethyl) -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2-benzyloxyphenyl) -5-methyl-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2-hydroxyphenyl) -5-methyl-3H-quinazolin-4-one; 2- (1- (2-amino-9H-purin-6-ylamino) ethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 5-methyl-2- [1- (9H-purin-6-ylamino) propyl] -3-o-tolyl-3H-quinazolin-4-one; 2- (1- (2-fluoro-9H-purin-6-ylamino) propyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (1- (2-amino-9H-purin-6-ylamino) propyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (2-Benzyloxy-1- (9H-purin-6-ylamino) ethyl) -5-methyl-3-o-tolyl-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-methyl-3-. { 2- (2- (1-methylpyrrolidin-2-yl) -ethoxy) -phenyl} -3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -3- (2- (3-dimethylamino-propoxy) -phenyl) -5-methyl-3H-quinazolin-4-one; 2- (6-aminopurin-9-ylmethyl) -5-methyl-3- (2-prop-2-ynyloxyphenyl) -3H-quinazolin-4-one; 2- (2- (1- (6-aminopurin-9-ylmethyl) -5-methyl-4-oxo-4H- quinazolin-3-yl] -phenoxy} -acetamide; 5-Chloro-3- (3,5-difluoro-phenyl) -2- [1- (9H-purin-6-ylamino) -propyl] -3H-quinazolin-4-one; 3-phenyl-2- [1- (9H-purin-6-ylamino) -propl] -3H-quinazolin-4-one; 5-fluoro-3-phenyl-2- [1- (9H-purin-6-ylammon) -propyl] -3H-quinazolin-4-one; 3- (2,6-difluoro-phenyl) -5-methyl-2- [1- (9H-purin-6-ylamino) -propl] -3H-quinazolin-4-one; 6-fluoro-3-yl-2- [1 - (9H-purin-6-ylammon) -ethyl] -3H-quinazoln-4-one; 3- (3,5-difluoro-phenyl) -5-methyl-2- [1- (9H-purin-6-ylamino) -ethyl] -3H-quinazolin-4-one; 5-fluoro-3-phenyl-2- [1- (9H-purin-6-lalamine) -etl] -3H-quinazolin-4-one; 3- (2,3-difluoro-phenyl) -5-methyl-2- [1 - (9H-purin-6-ylamino) -ethyl] -3H-quinazolin-4-one; 5-methyl-3-phenyl-2- [1 - (9H-purin-6-ylammon) -etl] -3H-quinazolin-4-one; 3- (3-Chloro-phenyl) -5-methyl-2- [1- (9H-purin-6-ylamino) -ethyl] -3H-quinazolin-4-one; 5-methy1-3-pheny1-2 - [(9H-purin-6-ylamino) -methyl] -3H-quinazolin-4-one; 2 - [(2-amino-9H-purin-6-ylamino) -methyl] -3- (3,5-difluoro-phenyl) -5-methyl-3H-quinazolin-4-one 3-. { 2 - [(2) -dethoxylamino-ethyl) -methyl-amino] -phenyl] -5-methyl-2 - [(9H-purin-6-ylamino) -methyl] - 3 H -quinazolin-4-one; 5-chloro-3- (2-fluoro-phenyl) -2 - [(9H-purin-6-ylamino) -methyl] -3H-quinazolin-4-one; 5-chloro-2 - [(9H-purin-6-ylammon) methyl] -3-o-tolyl-3H-quinazolin-4-one; 5-chloro-3- (2-chloro-phenyl) -2 - [(9H-purin-6-ylamino) -methyl] -3H-quinazolin-4-one; 6-fluoro-3- (3-fluoro-phenyl) -2- [1- (9H-purin-6-ylamino) -ethyl] -3H-quinazolin-4-one; 2- [1- (2-amino-9H-purin-6-ylamino) -ethyl] -5-chloro-3- (3-fluoro-phenyl) -5-fluoro-3H-quinazolin-4 -one; and its pharmaceutically acceptable salts and solvates. FORMULATIONS The compounds according to the ntion can be administered orally, transdermally, by inhalation, parenterally or sublingually. The compounds according to the ntion are in this case as active components in common administration forms, for example in compositions which essentially consist of an inert pharmaceutical carrier and a dose effective of the active ingredient such as, for example, tablets, dragees, capsules, seals, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems, etc. An effective dose of the compounds according to the ntion is, in the case of an oral application, between 0.1 and 5000, preferably between 1 and 500, particularly preferably between 5-300 mg / dose, and in the case of intravenous, subcutaneous or intramuscular application, between 0.001 and 50, preferably between 0.1 and 10 mg / dose. As inhalable administration forms, inhalation powders, metering aerosols containing propellant gases or inhalation solutions free of propellant gases are considered. In the context of the present ntion, sterile inhalation concentrates or solutions ready to be used are also included in the expression of propellant-free inhalation solutions. For the application by inhalation, the use of powders, ethanolic or aqueous solutions is preferred. For inhalation, according to the ntion, solutions containing 0.01 to 1.0, preferably 0.1 to 0.5%, of active principle are suitable. It is also possible to use the compounds according to the ntion as an infusion solution, preferably in a physiological solution of sodium chloride or in a nutrient saline solution. The compounds according to the ntion can be used alone or in combination with other active ingredients according to the ntion, optionally also in combination with other pharmacologically active ingredients. Suitable forms of application are, for example, tablets, capsules, suppositories, solutions, juices, emulsions or dispersible powders. Corresponding tablets can be obtained, for example, by mixing the active ingredient (s) with known adjuvants, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrating agents such as corn starch or alginic acid, binding agents such as starch or gelatin, lubricating agents such as magnesium stearate or talc, and / or agents for achieving the deposition effect such as carboxymethylcellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also consist of several layers. Correspondingly, the tablets may be produced by coating cores, produced analogously to the tablets, with agents commonly used in coating of dragees, for example collidon or shellac, gum arabic, talcum, titanium dioxide or sugars. To achieve a deposit effect or to avoid incompatibilities, the core may also consist of several layers. Similarly, in order to achieve a depositing effect, the coating of the tablet can also be made up of several layers, the aforementioned coadjuvants can be used in the case of tablets. Juices of the active principles or combinations of active ingredients according to the invention can additionally contain a sweetener such as saccharin, cyclamate, glycerin or sugars, as well as a flavoring agent, for example flavoring substances such as vanillin or orange extract . In addition, they may contain suspending aids or thickening agents such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective substances such as p- hydroxybenzoates Solutions for injection are prepared in a customary manner, for example under the addition of preserving agents such as p-hydroxybenzoates, or stabilizers such as alkali metal salts of ethylenediaminetetraacetic acid and packed in injection vials or ampoules. Capsules containing one or more active ingredients or combinations of active ingredients can be prepared, for example, by mixing the active ingredients with inert carriers such as lactose or sorbitol and encapsulating them in gelatin capsules. Suitable suppositories can be prepared, for example, by mixing with expected foreseen support agents, such as neutral fats or polyethylene glycol or their derivatives. Inhalable powders employable according to the invention may contain the active principle according to the invention alone or in a mixture with suitable, physiologically safe adjuvants. If the active compounds according to the invention are contained in a mixture with physiologically safe excipients, the following physiologically safe adjuvants can be used for the preparation of these inhalable powders according to the invention: monosaccharides (for example glucose or arabinose), disaccharides (for example lactose, sucrose, maltose), oligo- and poly-saccharides (for example dextrans), polyalcohols (for example sorbitol, mannitol, xylitol), salts (for example sodium chloride, calcium carbonate) or mixtures thereof coadjuvants with each other. Preferably, mono- or di-saccharides are used, with the use of lactose or glucose being preferred, especially, but not exclusively in the form of their hydrates As particularly preferred in the sense of the invention, lactose is used, lactose monohydrate being most preferred as an adjuvant. In the context of the inhalation powders according to the invention, the adjuvants have a maximum average particle size of up to 250 μm, preferably between 10 μm and 150 μm, particularly preferably between 15 μm and 80 μm μm. Eventually, it may be convenient to add by mixing to the aforementioned coadjuvants fractions of finer coadjuvants with an average particle size of 1 to 9 μm. The finer coadjuvants mentioned lastly are also chosen from the above-mentioned group of adjuvants which can be used. Finally, for the production of the inhalation powders according to the invention, micronized active principles according to the invention can be added by mixing, preferably with an average particle size of from 0.5 to 10 μm, particularly preferably from 0.5 to 10 μm. 1 to 5 pm, to the mixture of adjuvants. Procedures for the preparation of the inhalation powders according to the invention by grinding and micronization, as well as subsequent mixing of the components are known in the state of the art. The inhalation powders according to the invention can be applied by inhalers known from the state of the art. Inhalation aerosols containing propellant gases according to the invention may contain active ingredients according to the invention dissolved in the propellant gas or in dispersed form. The propellant gases which can be used for the production of inhalation aerosols are known from the state of the art. Suitable propellant gases are chosen from group consisting of hydrocarbons such as n-propane, n-butane or isobutane, and halogenated hydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The aforementioned propellant gases can be used here alone or in mixtures thereof. Particularly preferred propellant gases are halogenated alkane derivatives, chosen from TG134a and TG227 and mixtures thereof. Inhalation aerosols containing propellant gases may contain, in addition, other components such as co-solvents, stabilizers, surfactants (surfactants), antioxidants, lubricants, as well as agents for adjusting the pH value. All these components are known from the state of the art. The inhalation aerosols with content of propellant gases, mentioned above, can be applied by means of inhalers known from the state of the art (MDIs = metered dose inhalers). In addition, the application of the active principles according to the invention can be carried out in the form of inhalation solutions and inhalation suspensions free of propellant gases. Suitable solvents are aqueous or alcoholic solutions, preferably ethanolic, for this purpose. The solvent can be exclusively water or it is a mixture based on water and ethanol. The relative proportion of ethanol to water is not limited, but preferably the maximum limit is up to 70 volume percent, in particular up to 60 volume percent and, especially preferably, up to 30 percent in volume. volume. The rest Percentages in volume are completed by water. The solutions or suspensions containing the active principle according to the invention are adjusted with suitable acids to a pH value of 2 to 7, preferably 2 to 5. For the adjustment of this pH value, acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and / or phosphoric acid. Examples of particularly suitable organic acids are: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or propionic acid and others. Preferred inorganic acids are hydrochloric acid and sulfuric acid. It is also possible to use acids which already form one salt by addition of acids with one of the active ingredients. Among the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. Optionally, mixtures of the aforementioned acids can also be used, in particular in the case of acids which, in addition to their acid properties, also possess other properties, for example as flavoring, antioxidant or complexing substances such as, for example, citric acid or ascorbic acid. According to the invention, hydrochloric acid is particularly preferably used for adjusting the pH value. In these formulations, the addition of editic acid (EDTA) or one of its known salts, sodium edetate, as a stabilizer or complexing agent may optionally be waived. Other embodiments contain this or these compounds. In a preferred embodiment of this type, the content, referred to sodium edetate, is below 100 mg / 100 ml, preferably below 50 mg / 100 ml, so particularly preferred below 20 mg / 100 ml. In general, inhalation solutions are preferred, in which the content of sodium edetate is from 0 to 10 mg / 100 ml. To the inhalation solutions free of propellant gases, co-d solvents and / or other adjuvants can be added. Preferred co-solvents are those containing hydroxyl groups or other polar groups, for example alcohols - especially isopropyl alcohol, glycols - especially propylene glycol, polyethylene glycol, polypropylene glycol, glycol ethers, glycerol, poly (oxyethylene alcohols) and fatty acid esters of polyoxyethylene. By "adjuvants and additives" is meant in this respect any pharmacologically compatible substance, which is not an active ingredient, but which, together with the active ingredient (s), can be formulated in the pharmacologically suitable solvent in order to improve the qualitative properties of the formulation of active ingredients. Preferably, these substances do not display any pharmacological effect or, in the context with the intended therapy, they do not display any pharmacological effect worthy of mention or, at least, undesired. Adjuvants and additives include, for example, surfactants such as, for example, soya lecithin, oleic acid, sorbitan esters such as polysorbates, polyvinylpyrrolidone, other stabilizers, complexing agents, antioxidants and / or preservatives, which guarantee or they prolong the duration of use of the finished drug formulation, flavoring substances, vitamins and / or other additive substances known from the state of the art. Additive substances also include pharmacologically harmless salts, such as, for example, sodium chloride as an isotonifier.

Antioxidants, such as, for example, ascorbic acid, belong to the preferred adjuvants, insofar as they have not already been used for the adjustment of the pH value, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins that appear in the organism. human. Can be used preservatives, in order to protect the formulation against contamination with germs. Suitable preservatives are those known from the prior art, in particular cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate, in the concentration known from the state of the art. The preservatives mentioned above are preferably contained in concentrations of up to 50 mg / 100 ml, especially preferably between 5 and 20 mg / 100 ml. Preferred formulations contain, in addition to the solvent, water and the active principle according to the invention, and only benzalkonium chloride and sodium edetate. In another preferred embodiment sodium edetate is dispensed with. A therapeutically effective daily dose ranges from 1 to 2000 mg, preferably 10-500 mg per adult. The following Examples illustrate the present invention, but without limiting its scope: Pharmaceutical formulation examples A) Tablets per tablet active ingredient 100 mg lactose 140 mg corn starch 240 mg polyvinyl pyrrolidone 15 mg magnesium stearate 5 mg 500 mg The finely ground active ingredient, lactose and a part of the corn starch are mixed together. The mixture is screened, after which it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried. The granulate, the rest of the corn starch and the magnesium stearate are sieved and mixed together. The mixture is pressed to form tablets of suitable shape and size. B) Tablets per tablet active ingredient 80 mg corn starch 190 mg lactose 55 mg microcrystalline cellulose 35 mg polyvinyl pyrrolidone 15 mg sodium carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg The finely ground active ingredient, a part of corn starch , lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sifted and processed with the rest of the corn starch and water to form a granulate, which is dried and sieved. To this the sodium carboxymethyl starch and the magnesium stearate are added, mixed and the mixture pressed to form tablets of suitable size.

C) Dragees by dragee active substance 5 mg corn starch 41.5 mg lactose 30 mg polyvinyl pyrrolidone 3 mg magnesium stearate 0.5 mg 80 mg The active substance, corn starch, lactose and polyvinylpyrrolidone are mixed well and are moistened with water. The wet mass is passed through a sieve with a mesh width of 1 mm, dried at approx. 45 ° C and then the granulate is passed through the same sieve. After the addition of magnesium stearate, compressed cores with a diameter of 6 mm are pressed into a tablet machine. The dragee cores, thus produced, are coated, in a known manner, with a layer consisting essentially of sugar and talc. The finished tablets are polished with wax. D) Capsules per capsule active ingredient 50 mg corn starch 268.5 mg magnesium stearate 1.5 mg 320 mg The substance and corn starch are mixed and moistened with water. The wet mass is sifted and dried. The dried granulate is screened and mixed with magnesium stearate. The final mixture is packaged in capsules of Hard gelatin size. E) Blister solution active ingredient 50 mg sodium chloride 50 mg Aqua pro iny. 5 ml The active ingredient is dissolved in water at its own pH or, optionally, at pH 5.5 to 6.5 and mixed with sodium chloride as an isotonifier. The obtained solution is filtered under pyrogenic conditions and the filtrate is packed in aseptic conditions in ampoules, which are then sterilized and melted. The ampoules contain 5 mg, 25 mg and 50 mg of active ingredient. F) Suppositories active ingredient 50 mg solid fat 1650 mg 1700 mg Hard fat melts. At 40 ° C the active substance disperses homogeneously. It is cooled to 38 ° C and poured into weakly cooled suppository molds. G) Oral suspension active ingredient 50 mg hydroxyethylcellulose 50 mg sorbic acid 5 mg sorbitol (70%) 600 mg glycerin 200 mg aroma 15 mg Water up to 5 mi Distilled water is heated up to 70 ° C. In it, hydroxyethyl cellulose is dissolved with agitation. After the addition of sorbitol and glycerin solution, it is cooled to room temperature. At room temperature, sorbic acid, aroma and substance are added. To ventilate the suspension, the vacuum is made with agitation. H) Dosing aerosol (suspension) active ingredient 0.3% by weight sorbitan trioleate 0.6% by weight HFA134A: HFA227 2: 1 99.1% by weight The suspension is packaged in a conventional aerosol container with a metering valve. For each drive, preferably 50 μ? of suspension. The active principle can also be dosed in greater quantity. I) Dosage aerosol (solution) active substance 0.3% by weight ethanol abs. 20% by weight aqueous HCl 0.01 mol / l 2.0% by weight HFA134A 77.7% by weight The preparation of the solution is usually carried out by mixing the different components. I) Powder of inhalation active ingredient 80 pg lactose monohydrate up to 10 mg. The preparation of the inhalation powder is carried out in a usual by mixing the different components.

Claims

CLAIMS 1.- Compounds of the general formula (I) wherein R 1 signifies hydrogen, CO-CH 3, CO-CH 2 -R 4, CO-CHMe-R 4, CO-OR 4, CO-SR 4, CO-NH 2 or CO-NHR 4; R 2 means a radical selected from the group consisting of C 3-6 cycloalkyl, C 1-4 cycloalkyl C 3-6 alkyl, C 2-4 alkenyl C 3-6 cycloalkyl, C 2-4 alkynyl C 3-6 cycloalkyl, C 5-6 cycloalkenyl, alkyl Ci-6-cycloalkenyl C5-6, C2-4 alkenyl-C5-6-cycloalkenyl, C2-4-alkynyl-C5-6 cycloalkenyl, C5-6 cycloalkynyl, Ci-6-cycloalkynyl C5-6 alkyl, C2-4 alkenyl-cycloalkynyl C5-6 and C2-4 alkynyl-C5-6cycloalkynyl, which may optionally be substituted with one or two of the radicals CH3, F, OCH3, OH or NH2; R3 means a radical selected from the group consisting of C6-Ci aryl, Ci-6-aryl, C6-Ci aryl, C2-6 alkenyl-C6-Ci4 aryl, C2-6 alkynyl-C6-aryl, C5-C10 heteroaryl , Ci.i.sub.2-C5-C10 heteroaryl, C3-y2-alkenyl-C5-C10-heteroaryl, C3-y2-alkynyl-C5-C10-heteroaryl, C3-6 cycloalkyl, Ci.sub.6 alkyl-C3-6 cycloalkyl, C2.4-alkenyl. -C3-6cycloalkyl, C2-4 alkynyl-C3-6 cycloalkyl, C5-6 cycloalkenyl, C5-6 cycloalkenyl alkyl, C2-4 alkenyl-C5-6 cycloalkenyl > C 2-4 alkynyl-C 5-6 cycloalkenyl, C 5-6 cycloalkynyl, C 1-6 alkylalkyl C 5-6 cycloalkynyl, C 2-4 alkenyl C 5-6 cycloalkynyl and
C 2-4 alkynyl C 5-6 cycloalkynyl, which may optionally be substituted with a radical R 5 and up to three R 6 radicals; optionally substituted, wherein n, m, independently of one another, means 1 or 2; R4 means a radical optionally substituted, selected from the group consisting of Ci-4 alkyl, C2-io alkenyl, C2-io alkynyl, C3-6 cycloalkyl-Ci-4 alkyl, C3-6 cycloalkyl-C3-alkenyl, cycloalkyl C3- 6-C3-yl alkynyl, C6-Ci4 aryl, C6-Ci4 arylCi-4 alkyl, C5-Ci0 heteroaryl, C5-C10 heteroaryl-Ci-4 alkyl and haloalkyl; R5 means CONR8R9, NR8COR9, NR8R9, OR9 and -C1-4alkyl-CONR8R9; R6, the same or different, mean F, Cl, Br, OH, CN, CF3, CHF2 or a possibly substituted radical, selected from the group consisting of O-alkyl Ci-3, O-alkenyl C3-4, O-alkynyl C3- 4, Ci-3 alkyl, C 2-6 alkenyl and C 2-3 alkynyl, C 3-6 cycloalkyl-Ci-4 alkyl, C 3-6 cycloalkyl-C 2-4 alkenyl, C 3-6 cycloalkyl-C 2-4 alkynyl, cycloalkenyl Cs- e-C1-4 alkyl, C5-6 cycloalkenyl-C3-0 alkenyl, C5-6 cycloalkenyl-C2-4 alkynyl, C6-C14 arylC1-4 alkyl, C6-4 aryl C4-4 alkenyl, aryl C6- C 14 -C 4 alkynyl, C 1 -C 4 heteroaryl C 1-4 alkyl, C 2 -C 4 heteroaryl C 2-4 alkenyl and C 2-4 heteroaryl C 1-4 alkynyl, R 7 signifies hydrogen, COR 9, CONR 8 R 9 or a radical, selected from the group consisting of C-MO alkyl, C3-10 alkenyl, C3-io alkynyl, C3-6 cycloalkyl-C1- alkyl, C3-6 cycloalkyl-C3-alkenyl, C3-6 cycloalkyl-C3-alkynyl, cycloalkenyl C5-6-Ci-4 alkyl, C5-6 cycloalkenyl-C3-10 alkenyl, C5-6 cycloalkenyl-C3-alkynyl, C6-C4 aryl, Ci-i0-alkylaryl ril C6-
Cu, C2-io-C6-C4 alkenyl, C2-C0-alkynyl-C6-Ci4-aryl, C5-C10-heteroaryl, Ci-12-heteroaryl-C10-alkyl, C3-12-alkenyl-C5-C10-heteroaryl and alkynyl C3-i2-C5-C10 heteroaryl, which may optionally be substituted with a radical R14 and with a radical R15; R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of alkyl d-10, alkenyl C3-io, alkynyl C3-i0, cycloalkyl C3-6-alkyl Ci-4, cycloalkyl C3-6-alkenyl 03-10, C3-6 cycloalkyl-C3-alkynyl, C5-6cycloalkenyl-C1-4alkyl, C5-6cycloalkenyl-C3-alkenyl, C5-6cycloalkenylC3.10 alkynyl, C6-C14 aryl-C4alkyl, aryl C6-Ci-C3-10 alkenyl, and C6-10 aryl C6-C3-10 alkynyl, C5-C10 heteroaryl, C5-C6 heteroaryl C1-4 alkyl, C5-C10 heteroaryl C1-4 alkenyl, C5-C6 heteroaryl C 1-4 alkynyl, C 1-4 alkyl-C 2-4 alkyl, C 1-4 alkynyl-C 4-6 alkenyl, and C 1-4 alkyl-O-C 1-6 alkynyl R 9 means hydrogen or a radical, optionally substituted , selected from the group consisting of C1-12 alkylC3-C2 alkenyl, C3-C2 alkynyl, C3-6 cycloalkyl-C1-12 alkyl, C3-6 cycloalkyl-C3-2 alkenyl, C3-6 cycloalkyl-C3-alkynyl2, C5-6 cycloalkenyl-C1-4alkyl , C5-6 cycloalkenyl-C3-10 alkenyl, C5-6 cycloalkenyl-C3-10 alkynyl, C6-C14 aryl-C1-12alkyl, C6-Ci4alkynyl-C3-alkenyl2, aryl C6-Ci4-C3-12 alkynyl , C6-C14 aryl, Ci-12 alkyloxy C6-Ci4 alkenyl C2-i2 alkenyl-C6-C1 aryl, C2-12 alkynyl-C6-Ci4 aryl, C5-C10 heteroaryl, C5-Ci0 heteroaryl Ci-12 alkyl, C5-C10 heteroaryl-C3-y2 alkenyl, C5-Ci2 heteroaryl-C3-alkynyl, C3-8 cycloalkyl, C5-8 cycloalkenyl, NR11R12-C3-8 cycloalkyl, NR11R12-C5-8 cycloalkenyl and NR11R12-cycloalkynyl
C5-8 or means a heterocycloalkyl radical 3-8 - (???), optionally substituted contains at least one NR10 group in the 3- to 8-membered heterocycle, or R8 and R9 together form a 4- to 7-membered, saturated or unsaturated alkyl bridge, optionally containing an O atom or a S (O) p group , where p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a 5- to 6-membered heterocycle, optionally containing another N atom and optionally substituted with a radical selected from the group consisting of R10, NR11R12 and NR1 R12Ci-alkyl, or means a radical wherein z, q, g, d, independently of one another, means 1, 2 or 3; R 0 means hydrogen or a radical, optionally substituted, selected from the group consisting of C-MO alkyl, C 3-7 alkenyl β -, C 3 - alkynyl, C 3-7 cycloalkyl - C 0 alkyl, C 3-7 cycloalkyl - alkenyl C3-io, C3-7 cycloalkylC3-io alkynyl, C3- cycloalkyl, Ci-6-cycloalkyl C3-7 alkenyl, C2-4 alkenyl-C3-7 cycloalkyl, C2-4 alkynyl-C3-7 cycloalkyl, tetrahydropyranyl and (NR4) 2CH-CMO alkyl, R1 1, R12, equal or different, mean hydrogen or a radical, optionally substituted, selected from the group consisting of alkyl C-MO, C3-C0 alkenyl, C3-C0 alkynyl, C3-6 cycloalkylC1-4 alkyl and C3-6 cycloalkyl or R11 and R2 together form an alkyl chain of 4 to 7 members, which optionally contains a heteroatom R 3 is F, Cl, Br, OH, CN, CF 3, CHF 2 or C 1-4 alkyl-O-, R 14 is NR 11 R 12 or optionally substituted C 3-8 heterocycloalkyl radical (CH 2) q which contains at least one group NR10 in the 3- to 8-membered heterocycle, or R13 R14 together form a saturated or unsaturated 4 to 7 membered alkyl bridge, optionally containing an O atom or a S (O) p group, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereoisomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids, solvates and hydrates. 2. Compounds according to claim 1, wherein R1 and R3 to R14 can have the indicated meanings and R2 means a radical, optionally substituted with one or two of the radicals CH3, F, OCH3, OH or NH2, selected from the group consisting of in C3-6 cycloalkyl, Ci-6-cycloalkyl C3-6 alkyl and C2-4 alkenyl-C3-6 cycloalkyl. 3. Compounds according to claim 1 or 2, wherein R1, R2 and R4 to R14 may have the indicated meanings and R3 means a radical, selected from the group consisting of phenyl and C5-6 cycloalkyl, which may optionally be substituted with a radical R5 and with up to three radicals R6, or , optionally substituted, wherein n, m, independently of one another, means 1 or 2. 4. Compounds according to one of claims 1 to 3, wherein R1 to R7 and R10 to R14 can have the indicated meanings and R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of CMO alkyl, C3-10 alkenyl, C3-io alkynyl and Ci-4-alkylC 2-4 alkyl, R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of group consisting of Ci-12 alkyl, C3-alkenyl2, C3-12 alkynyl. C3-6 cycloalkyl Ci-i2 alkyl, C6-Ci4 aryl, Ci -i2 alkyiC6-Ci4 aryl, C2-i2 alkenyl C6-C1 aryl, C2-i2 alkynyl-C6-Ci4 aryl, C5-Ci0 heteroaryl, heteroaril Cs-C-io-Ci -i2 alkyl, C3-i2 heteroaryl-alkenyl, C3-12 heteroaryl-alkynyl, C3-8 cycloalkyl, C5-8 cycloalkenyl and NR1 1 R12-cycloalkyl
C3-8, O means a C3-8- (CH2) q-, optionally substituted heterocycloalkyl, which contains at least one group NR10 in the 3- to 8-membered heterocycle, or R8 and R9 together form an alkyl bridge of 4 to 7 members, saturated or unsaturated, which optionally contains an O atom or a S (O) P group, where p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a 5-6 membered heterocycle, which eventually contains another N atom and which is optionally substituted with a radical selected from the group consisting of R10, NR R12 and NR 1R12alkyl C1-, or means a radical N (CH2) 2 < / (CH2) q
(CH2) g < (CH2) d N
I R10 wherein z, q, g, d, independently of one another, means 1, 2 or 3. 5. Compounds according to one of claims 1 to 4, wherein R a R7 and R10 a R14 may have the meanings indicated and R8 means hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-10 alkyl, C3-io alkenyl, C3-io alkynyl, and Ci-4-O-alkyl Ci-4 alkyl, R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of Ci-12 alkyl, C3-alkenyl2, C3-alkynyl2, C3-6 cycloalkyl-C1-i2alkyl, C6-Ci aryl, Ci -i2 alkyiC6-C14 alkyl, C2- alkenyl i2-C6-Ci4-aryl, C2-C2-alkynyl-C6-Ci4-aryl, C5-Ci0-heteroaryl, C5-Cio-heteroaryl Ci -i2-alkyl, C3-I2-heteroaryl-alkenyl, C3-12-heteroaryl-alkynyl, C3-8-cycloalkyl , C5-8 cycloalkenyl and NR11R12-cycloalkyl or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12)
OR R8 and R9 together form a 4 to 7 membered saturated or unsaturated alkyl bridge, which optionally contains an O atom or a S (O) p group, where p, q, independently of one another, mean 0, 1 or 2; or NR8R9 means a radical, optionally substituted, selected from the group consisting of the general formulas (B1) to (B8) wherein?, q, g, d, independently of one another, means 1, 2 or 3. 6. Compounds according to one of claims 1 to 5, wherein R1 to R8 and R10 to R12 can have the meanings indicated and R7 means COR9 or CONR8R9. 7. - Compounds according to one of claims 1 to 6, wherein R1 to R5 and R7 to R14 may have the indicated meanings and R6, same or different, mean F, Cl, CF3, or an O-alkyl radical Ci-3 or Ci-3 alkyl, optionally substituted. 8. Compounds according to one of claims 1 to 7, wherein R4 to R6 and R10 to R12 can have the indicated meanings and R1 means CO-CH3, CO-CH2-R4 R2 means cyclopropyl, which may optionally be substituted with one or two of radicals CH3, F, OCH3, OH or NH2, R3 means , optionally substituted, wherein n, m, independently of one another, means 1 or 2; R7 means hydrogen, COR9 or CONR8R9, R8 means hydrogen or CMO alkyl, R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of C3-8 cycloalkyl and NR1 1 R12-C3-8 cycloalkyl, or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12)
(A10) (A11) (A12)
Or NR8R9 means a 5- to 6-membered heterocycle, containing 1 to 3 N atoms, which is optionally substituted with a radical selected from the group consisting of R10, NR1 R12 and NR11R12C1-4alkyl. 9. Compounds according to claim 1 to 7, wherein R4 to R6 and R10 to R12 can have the indicated meanings and R1 means CO-CH3, CO-CH2-R4 R2 means cyclopropyl, which may optionally be substituted with one or two of radicals CH3, F, OCH3, OH or NH2, R3 means optionally substituted, wherein n, m, independently of one another, means 1 or 2; R7 means hydrogen, COR9 or CONR8R9, R8 means hydrogen or CMO alkyl, R9 means hydrogen or a radical, optionally substituted, selected from the group consisting of C3-8 cycloalkyl and NR1 1R12-C3-8 cycloalkyl. or means a radical, optionally substituted, selected from the group consisting of the general formulas (A1) to (A12)
NR R means a 5- to 6-membered heterocycle, containing 1 to 3 N atoms, which is optionally substituted with a radical selected from the group consisting of R 10, NR 1R 12 and NR 1 R 12 C 1-4 alkyl. 10. Compounds according to one of claims 1 to 9 for use as a medicine. 11. Use of the compounds according to one of claims 1 to 9 for the preparation of a medicament for the treatment of diseases, in whose pathology an activity of PI3-kinases participates, in which therapeutically effective doses of the compounds of the formula (I) can display a therapeutic utility.
12. - Use according to claim 11, characterized in that it is inflammatory and allergic diseases of the respiratory tract.
13. - Use according to claim 1 1 or 12, characterized in that it is a disease that is selected from the group consisting of chronic bronchitis, acute bronchitis, bronchitis as a result of bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, bronchitis chronic obstructive (COPD), asthma (intrinsic or allergic), pediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, cystic fibrosis or mucoviscidosis, lack of alpha-1-antitrypsin, cough, pulmonary emphysema, pulmonary diseases interstitial, alveolitis, hyperreactive airways, nasal polyps, pulmonary edema, pneumonitis by virtue of different genesis, such as induced by irradiation or by infectious aspiration or collagenosis, such as lupus erythematosus, systemic scleroderma, sarcoidosis and Boeck's disease.
14. - Use according to claim 1, characterized in that it is inflammatory and allergic diseases of the skin.
15. Use according to claim 1 or 14, characterized in that it is a disease that is chosen from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, Alopecia areata (circular hair loss), erythema exudative multiforme ( Stevens-Johnson), dermatitis herpetiformis, scleroderma, vitiligo, hives (urticaria), lupus erythematosus, follicular and flat pyoderma, endogenous and exogenous acne, acne rosacea, as well as other inflammatory and allergic or proliferative skin diseases.
16. - Use according to claim 1, characterized in that it is inflammations in the eye.
17. - Use according to claim 1 or 16, characterized in that it is a disease that is chosen from the group consisting of inflammation of the conjunctiva (conjunctivitis) of different types such as, for example, infections with fungi or bacteria, allergic conjunctivitis, irritant conjunctivitis, drug-induced conjunctivitis, keratitis and uveitis.
18. Use according to claim 1, characterized in that it concerns diseases of the nasal mucosa.
19. - Use according to claim 1 or 18, characterized in that it is a disease that is chosen from the group consisting of allergic rhinitis, allergic sinusitis and nasal polyps.
20. - Use according to claim 1, characterized in that it is inflammatory or allergic pathological states in which autoimmune reactions take place.
21. - Use according to claim 1 or 20, characterized in that it is a disease that is selected from the group consisting of Crohn's disease, ulcerative colitis, systemic lupus erythematosus, chronic hepatitis, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis. , rheumatoid spondylitis.
22. Use according to claim 11, characterized in that it is inflammations of the kidneys.
23. - Use according to claim 1 or 22, characterized in that it is a disease that is chosen from the group consisting of glomerulonephritis, interstitial nephritis and idiopathic nephrotic syndrome.
24. - Pharmaceutical formulation containing a compound of formula (I) according to one of claims 1 to 9.
25. Pharmaceutical formulation applicable by inhalation according to claim 24 which contains a compound of the formula (I) according to one of the claims 1 to 9.
26.- Pharmaceutical formulation applicable orally according to claim 24 which contains a compound of the formula (I) according to one of the claims 1 to 9.
27.- Combinations of drugs that, together with one or more The compounds of the formula (I) according to one of claims 1 to 9 contain, as another active ingredient, one or more compounds which are selected from the classes of betamimetics, anticholinergics, corticosteroids, other PDE4 inhibitors, LTD4 antagonists, inhibitors. of EGFR, dopamine agonists, H1 antihistamines, PAF antagonists and PI3-kinase inhibitors or combinations of two or three thereof.
28.- Process for the preparation of compounds of the general formula (VI), in which the radical R2 can have the indicated meanings, R3 'means an optionally substituted radical, selected from the group consisting of 4-PhCOOMe, 4-PhNO2, 4-piperidyl, cis / trans-4-alkoxycarbonylcyclohexyl and 4-methoxycarbonyl-methyl phenyl, and Y = CC alkyl or -S-C 1 -C 4 alkyl, characterized in that (a) a compound of the formula (II) is reacted with a compound of the formula (III) wherein R2 can have the indicated meaning, and (b) the compound of formula (V), resulting from step (a), (IV) is reacted with a compound of the formula (V) H R3 NH2 (V) wherein R3 'may have the above indicated meaning, and is cyclized to form the compound of the formula (VI).
29. Process for the preparation of compounds of the general formula (Ib) wherein R 2, R 6, R 8 and R 9 can have the indicated meanings, G means phenyl or cyclohexyl, and X O or 1 characterized in that (a) a compound of the formula (Via) (Via) in which R2, R6 and Y can have the indicated meanings, is reacted, by means of an alkali metal hydroxide, to give a compound of the formula (VII) (VII) and (b) the compound of the formula (VII), resulting from step (a), is reacted with a compound of the formula (VIII) H (VIII) wherein R8 and R9 may have the indicated meanings, to give a compound of the formula (Ib).
30. Procedure for the preparation of compounds of the general formula (le) or (Id), wherein R2, R6, R8, R9 and Y can have the indicated meanings, characterized in that (a) a compound of the formula (Vlb) is reduced in a compound of the formula (IX) and the compound of the formula (IX), resulting from step (a), is reacted, by means of a reductive amination, to give a compound of the formula (le) or (Id).
31.- Procedure for the preparation of compounds of the general formula (le), (If) or (Ig), wherein R2, R7, R8, R9 and Y can have the indicated meanings, characterized in that a compound of the formula (Vlc ^ (Vlc) is reacted, by means of reductive amination, to give a compound of the formula (le), (If) or (Ig).
32.- Compounds of the general formula (VI) (VI), where R, Rs' and Y can have the indicated meanings, possibly in the form of their tautomers, their racemates, their enantiomers, their diastereoisomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids.
33.- Compounds of the general formula (IX) wherein R2, R6e and Y may have the indicated meanings, optionally in the form of their tautomers, their racemates, their enantiomers, their diastereoisomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids.
34.- Compounds of the general formula (VII) (VII) where R2, R6 and Y can have the indicated meanings, possibly in the form of their tautomers, their racemates, their enantiomers, its diastereoisomers and their mixtures, as well as, optionally, their salts by the addition of pharmacologically harmless acids.